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ABSTRACT 
The free fatty acid receptor 1 (FFA1), a G protein-coupled receptor (GPCR) naturally activated by 
long-chain fatty acids is a novel target for the treatment of metabolic diseases. The basic amine 
spirocyclic periphery of Eli Lilly’s drug candidate LY2881835 for treatment of type 2 diabetes 
mellitus (which reached phase I clinical trials) inspired a series of novel FFA1 agonists containing 
the 3-[4-(benzyloxy)phenyl]propanoic acid pharmacophore core decorated with a range of 
spirocyclic motifs. The latter were prepared via the Prins cyclization and subsequent modification 
of the 4-hydroxytetrahydropyran moiety in the Prins product. Here, we synthesize 19 compounds 
and test for FFA1 activity. Within this pilot set, a nanomolar potency (EC50 = 55 nM) was achieved. 
Four lead compounds (EC50 range 55 – 410 nM) were characterized for aqueous solubility, 
metabolic stability, plasma protein binding and Caco-2 permeability. While some instability in the 
presence of mouse liver microsomes was noted, mouse pharmacokinetic profile of the compound 
having the best overall ADME properties was evaluated to reveal acceptable bioavailability (F = 
10.3%) and plasma levels achieved on oral administration. 
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1. Introduction 
The free fatty acid receptor 1 (FFA1, known as GPR40 prior to its de-orphaning in 2003) promptly 
became a biological target of high importance from the standpoint of developing fundamentally 
new therapeutic agents against type 2 diabetes mellitus (T2DM). FFA1 agonists are capable of 
raising insulin levels but only do so in hyperglycemic state when the FFA1 expression is 
upregulated.
1
 The activation of FFA1 triggers a GPCR signaling cascade which invokes insulin 
secretion to normalize blood glucose levels. As a result, the expression of the receptor goes back to 
normal, desensitizing the insulin-producing machinery to FFA1 agonists still remaining in 
circulation.
2
 This is in sharp contrast to other antidiabetic agents, such as sulfonylureas, that 
continue stimulating insulin release irrespective of the current glucose levels and can, therefore, 
cause hypoglycemia (an adverse, potentially deadly condition).  
The extensive worldwide research efforts in the decade following FFA1 de-orphaning aimed at 
developing clinically useful FFA1 agonists
3
 were nearly halted after Takeda’s first-in-class agent 
fasiglifam (TAK-875) was discontinued in phase III of human trials.
4
 On the date of submission of 
this manuscript, only one FFA1 agonist (Piramal’s compound P11187 of undisclosed structure) was 
in clinical research.
5
 This is rather unfortunate as the efficacy profile of TAK-875, despite its 
idiosyncratic liver toxicity, was very good.
 6
 Therefore, if the toxicity profile of FFA1 agonists is 
diligently tackled, there remains an opportunity to bring the first drug in this class to market.
7
  
The toxicity of TAK-875 was debatably linked to its overly high lipophilicity.
7
 On the one hand, 
relatively high lipophilicity is likely a pre-requisite for ligand’s affinity to the receptor (considering 
the fact that its endogenous ligands are medium-to-long chain fatty acids
1
). On the other hand 
increasing the polarity (i. e. increasing the total polar surface area or lowering the LogP) of FFA1 
agonists could provide the solution to the toxicity problem. Recently, we reported potent and 
selective FFA1 agonists based on containing 1,3-oxazole, 1,2,4-oxadiazole
8
 and 1,2,4-thiadiazole
9-
10
 grafted onto or replacing the phenyl ring of the  3-[4-(benzyloxy)phenyl]propanoic acid core, 
which mimics the fatty acid endogenous ligands of the receptor and is present in TAK-875 and 
other advanced compounds of this class (such as Amgen’s AMG-837,11 and Eli Lilly’s 
LY2881835
3
) (Figure 1).  
 
Figure 1. Advanced GPR40 agonists containing the 3-[4-(benzyloxy)phenyl]propanoic acid core.  
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Besides the heterocyclic appendage
8
 or scaffold hopping
9-10
 approach realized in our previous 
studies, we became intrigued by the structure of LY2881835 and the presence of a basic amine 
center, in combination with the spirocyclic motif, in its periphery. Both aspects appeared quite 
appealing from the drug design standpoint. The basic center, which would likely be protonated at 
physiological pH, is capable of increasing hydrophilic character of LY2881835 itself or any related 
compounds. This was clearly a reassuring observation as high lipophilicity has been dogmatized as 
a pre-requisite to high ligand affinity toward FFA1 (we observed a significant activity drop on 
replacing the 3-phenylpropionic acid FFA1 pharmacophore with its more polar 1,3,4-thiadiazole 
congener
9
). Spirocyclic moieties are considered privileged moieties in GPCR ligand design due to 
their pronounced three-dimensional character, which ensures better complementarity of a small-
molecule ligand to its protein target and, as a result, fewer off-target effects.
11
 
The Prins cyclization involving cyclic ketones and homoallylic alcohol under Lewis or Brønsted 
acid catalysis provides a facile entry into spirocyclic motifs which contain a potentially reactive 
functionality originating from the interception of intermediate spirocyclic carbocation with various 
nucleophiles (thus resulting in a formal three-component process).
12
  Azacycloalkanones have been 
rarely employed as carbonyl components in the Prins cyclization, except for a comprehensive 
methodology report from the Ghosh group.
13
 Recently, we described a facile and convenient 
protocol to prepare spirocyclic amino alcohol building blocks from a range of azacycloalkanones.
14
 
In particular, N-Boc-protected 1-oxa-9-azaspiro[5.5]undecan-4-ol (1) which was amenable by this 
method on a multigram scale, was viewed as a particularly valuable building block to graft diverse 
spirocyclic periphery, similar to that of LY2881835, onto the 3-[4-(benzyloxy)phenyl]propanoic 
acid core, which common to many advanced FFA1 agonists (vide supra), via a reductive amination 
of aldehyde building block 2 with a range of amines 3 derived from 1.  
While 2 was lacking a substituent in position 3 of 3-phenylpropanoic carboxylate (which is present 
in many advanced compounds shown in Figure 1), we reasoned that the use of the simplified 
pharmacophore would allow streamlined screening for the optimal spirocyclic periphery in series 4. 
Once lead compounds are identified within the latter, appropriate substitutions in the 3-[4-
(benzyloxy)phenyl]propanoic acid portion of the future new agonists  can be defined and introduced 
(Figure 2). Herein, we describe the initial promising results related to the synthesis, biological and 
ADMET/PK profiling of compounds belonging to series 4.  
Figure 2. Design and retrosynthetic analysis of new series of FFA1 agonists 4. 
 
2. Results and discussion 
The synthesis of core aldehyde building block 2 commenced with known
15
 aldehyde 5. The Horner-
Wadsworth-Emmons olefination of the latter (using commercially available 6) gave cinnamate ester 
7. Facile hydrogenation of the double bond in 7 was achieved over Raney nickel without the 
disruption of the benzyl ether. Selective hydrolysis of the methyl ester in resulting tert-butyl 3-
phenylpropionate 8 and subsequent mixed anhydride reduction of carboxylic acid 9 furnished target 
building block 1 (Scheme 1).  
Scheme 1. Synthesis of core  aldehyde building block 1. 
 
The diverse set of periphery spirocyclic building blocks 3a-r was synthesized from progenitor 1 as 
summarized in Scheme 2. Sodium alkoxide, generated via treatment of 1 with sodium hydride in 
DMF, was alkylated with a set of alkyl halides to furnish, after Boc group removal, building blocks 
3a-g. 
Multigram-scale oxidation of 1 with PDC furnished ketone 10 which served as a starting material 
for preparation of the rest of building blocks 3h-r. The Wittig reaction of 10 with phosphonium 
ylides (generated by treatment of the respective phosphonium salts with n-BuLi) furnished 
respective olefins, all of which, except for unsubstituted methylene compound, were obtained as 
difficult-to-separate mixtures of E- and Z-isomers. After brief fractionation on silica gel, the olefin 
intermediates were hydrogenated over 10% Pd on carbon using ammonium formate as a source of 
hydrogen. Upon removal of the Boc group, a set of building blocks 3h-o was obtained. 
Considering the previous success in grafting polar heterocycles onto the periphery of FFA1 
agonists,
8
 we designed 1,2,4-oxadiazole containing spirocyclic piperidine building blocks 3p-r. The 
synthesis of the latter was achieved via a multistep reaction sequence which included Horner-
Wadsworth-Emmons olefination, reduction of the ,-unsaturate ester, alkaline hydrolysis of its 
saturated counterpart to provide common carboxylic acid starting material 11. Activation of the 
carboxylic functionality in the latter with isobutyl chloroformate followed by the reaction with the 
respective amidoximes, cyclodehydration of the resulting initial adducts on treatment with TBAF in 
refluxing toluene, and Boc group removal furnished target 1,2,4-oxadiazoles 3p-r (Scheme 2). 
Scheme 2. Synthesis of spirocyclic building blocks 3a-r.  
 
Reagents and conditions: i. NaH, DMF, 0 ºC, 30 min; ii. RHal, DMF, 0 ºC  r. t., 18 h; iii. TFA, 
CH2Cl2, 0 ºC, 6 h; iv. RCH2PPh3Cl, n-BuLi, THF, 0 ºC  r. t., 18 h; v. HCOONH4, 10% Pd-C, 
EtOH, reflux, 12 h; vi. TFA, CH2Cl2, 0 ºC, 6 h; vii. EtOOCCH2P(O)(OEt)2, NaH, THF, 0 ºC  r. t., 
18 h; viii.  HCOONH4, 10% Pd-C, EtOH, reflux, 12 h; ix. KOH, aq. MeOH, r. t., 18 h; x. i-
BuOOCCl, THF, N-methylmorpholine, -30 ºC, 30 min; xi. RC(NH2)=NOH, r. t., 12 h; xii. TBAF, 
toluene, reflux, Dean-Stark trap; xiii.  TFA, CH2Cl2, r. t. 18 h. 
Spirocyclic building blocks 3a-r thus synthesized (as well as commercially available unsubstituted 
1-oxa-9-azaspiro[5.5]undecane 12) were then employed in reductive amination of aldehyde 2 and, 
after brief fractionation of the tertiary amine products, the Boc protecting group was removed using 
TFA in CH2Cl2, followed by counter-ion exchange with HCl in diethyl ether, to furnish the target 
compounds 4a-s (Scheme 3). 
Scheme 3. Preparation of FFA1 agonists 4a-s studied in this work. 
 
It should be noted that, owing to difficulties we faced in purification of the hydrochloride products, 
which required repeated manipulation of semi-purified material, the isolated yields of compounds 
4a-s achieved in this study were relatively low (see ESI). Nonetheless, the synthetic strategy 
described above allowed the preparation of the required quantities of compounds 4a-s for the initial 
in vitro biological profiling of the lead compounds thus identified – for in vitro ADME and in vivo 
PK characterization. Further optimization of the synthesis of the frontrunner compounds will be 
needed before further development of the series disclosed herein. 
Potential FFA1 agonists 4a-s thus synthesized were tested for FFA1 activation using calcium flux 
assay employing Chinese hamster ovary (CHO) cells engineered to stably express human FFA1. All 
compounds were tested in dose-response (% FFA1 activation) mode in order to determined EC50 
values. The latter, as well as % of maximum efficacy achieved for active compounds relative to 
reference agonist GW9508
16
 (used at 5 M concentration throughout the study) are given in Table 
1. 
Table 1. FFA1 agonists 4a-r studied in this work. 
Compound R 
FFA1 EC50 ± SD, 
Ma 
% efficacy
b
 
 
4a Me >20.00 n/a 
4b Et >20.00 n/a 
4c 
 
>20.00 n/a 
4d 3-FC6H4CH2 1.30 ± 0.24 98 
4e 4-F3CC6H4CH2 >20.00 n/a 
4f PhCH2 1.16 ± 0.12 100 
4g 4-FC6H4CH2 2.01 ± 0.52 75 
 
4h H >20.00 n/a 
4i 4-F3CC6H4 1.27 74 
4j 3-FC6H4 >20.00 n/a 
4k 4-FC6H4 0.41 ± 0.07 88 
4l Ph 0.055 ± 0.011 93 
4m 4-MeOC6H4 0.28 ± 0.04 100 
4n 4-MeC6H4 0.077 ± 0.02 74 
4o 2-FC6H4 0.81 ± 0.21 95 
 
4p 3-Py >20.00 n/a 
4q 
 
4.54 ± 0.73 53 
4r MeOCH2CH2 >20.00 n/a 
 
4s H >20.00 n/a 
a
 Each value is an average of n = 4. 
b
 Relative to GW9508
16
 (5 M). 
On examination of the FFA1 activation data presented in Table 1 it becomes clear that in the newly 
designed series, increased lipophilicity (in combination with the basic nitrogen center counter-
balancing the lipophilic periphery) is the principal driver of potency, as it was described for FFA1 
agonists in a number of instances.
10,17
 This should be expected for receptors modulated by 
endogenous free fatty acids and for the ligands intended to mimic the lipophilic character of the 
latter. Indeed, the hydrophilicity imparted by unsubstituted 1-oxa-9-azaspiro[5.5]undecane 
periphery (compound 4s) was detrimental to the agonistic potency. However, introduction of alkoxy 
substituents of increasing size (compound 4a-g) gradually brought the potency back into low-
micromolar range. Of particular interest is the influence of alkyl substituents in the pyran portion of 
the new FFA1 agonist scaffold of the potency (exemplified by compounds 4h-o). Here, introduction 
of lipohilic benzyl periphery results in a significant potency increase, with the most compound (4l) 
having EC50 comparable to that of Takeda’s phase III compound TAK-875 (EC50 = 0.014 M).
18
 
Taking into account the size of the pilot set of compounds studied in this work, this attests to the 
success of the initial FFA1 design idea implemented in the new molecular scaffold. 
We next determined the selectivity profile of the most potent GPR40 agonists (4k-n) against other 
free fatty acid receptors (FFA3/GPR41, FFA2/GPR43 and FFA4/GPR120). FFA2 and FFA3 
agonists have a preference in binding short-chain fatty acids while FFA1 and FFA4 have a higher 
affinity to medium- and long-chain fatty acids.
19,20
 As it is seen from the activity data against this 
panel of GPCRs, the four lead compounds displayed high selectivity for FFA1 (Table 2).  
Table 2. Selectivity profile for compounds 4k-n.
a
 
 
4k 4l 4m 4n 
human FFA1/GPR40 EC50 (µM) 0.41 0.055 0.28 0.077 
human FFA3/GPR41 EC50 (µM) >10 >10 >10 >10 
human FFA2/GPR43 EC50 (µM) >10 >10 >10 >10 
human FFA4/GPR120 EC50 (µM) >10 >10 >10 >10 
a
 Each value is an average of n = 4 in the presence of 0.1% BSA.  
In order to better understand the dramatic influence of the benzyl substituent in the 1-oxa-9-
azaspiro[5.5]undecane portion of the compounds (compared to the unsubstituted derivative), we 
have docked 4l and 4s in the FFA1 binding site (Figure 3).  
 
Figure 3.  Docked poses of compounds 4l and 4s at FFA1. (A) Overlay of 4l (maroon) and 4s 
(green) in the FFA1 active site. (B) Hydrophobic interactions of the benzyl substituent. Protein-
Ligand interactions are visualized for compound 4l in A, only. Hydrogen bonds, π-π and 
hydrophobic interactions are in a brown, blue and yellow dashed-line, respectively. Each 
transmembrane helix is labeled in red roman numerals. Residues have been labeled with their 
position followed by the Ballesteros and Weinstein numbering
21
 in subscript.  
Both compounds occupy similar positions within the binding cativy, forming the critical hydrogen 
bonds with R1835.39, R2587.35, Y913.37 and Y2406.51. The propanoic acid moeity may be further 
stabilized by a network of π- π interactions that could occur between F883.34, F1424.61, W174EL2 and 
F873.33 of the receptor and the aromatic rings of each compound. However, there are signifigant 
differences in the positioning of the spiro-pyran moiety, which is likely responsible for the observed 
differences in the potency of 4l (EC50 = 0.055 M) and 4s (EC50 >20.00 M). In 4s, this moiety 
positions toward the extracellular side while, in contrast, the potent 4l adopts a position, where 1-
oxa-9-azaspiro[5.5]undecane faces toward the intercelluar side (Figure 3A). Here, the terminal 
benzyl substituent positions within a favorable hydrophobic cavity forming numerous hydrophobic 
interactioins with L542.51, L1354.54 and V813.27,, while also having π- π stacking interactions with 
W1314.50 (Figure 3B).  Together these contacts drive the benzyl-substituted 1-oxa-9-
azaspiro[5.5]undecane moiety deep into the phosopholipid bilayer, which might be benefical for 
agonist activity.  
 
Figure 4. (A) Overlay of 4l (maroon) and 4s (green) in the FFA1 active site in the presence of the 
predicted position of the lipid bilayer demonstrated by the lipid phosphate groups in the form of 
pink spheres. (B) Surface representation of the FFA1 that interfaces with the lipid bilayer with the 
docking pose of 4l (maroon) and 4s (green). The surface colors: white, green, blue and red 
correspond to hydrophobic, hydrophilic, negatively charged and positively charged residues, 
respectively. Each transmembrane helix is labeled in red roman numerals. 
To appreciate the positioning of the lipid bilayer and its possible interactions with the ligand tails, 
we used the Orientation of Proteins in Membrane (OPM) database and PPM webserver (REF: 27) to 
align and perdict the position of FFA1 in a membrane (Figure 4A).  The position of 4s within the 
binding cavity is seemlingly tolerable, however, the ligand stablity is likely compromised by the 
electrostatic interactions between the positively charged amonium of its spyrio-pyran motif and the 
negatively charged phospholipid head. Here, the fluidity of the lipid bi-layer coupled with these 
strong electrostatic interactions may destabalise the binding conformation, which likely attributes  
to the low activity of the compound. In contrast, the benzyl substituent of compound 4l favors the 
more hydrophobic environment (Figure 4B), positioning at the interface between the lipid tails and 
protein which negates the detrimental attraction between the phostphate heads and positively 
charged amonium.  
Since we were able to reach well into submicromolar potency range with our pilot set of 19 
compounds (4a-s), we were also keen on assessing the preliminary ADME profile of the most 
active compounds from this set (4k-n). On examination of the data presented in Table 3, several 
general observations can be made. All four compounds displayed satisfactory aqueous solubility 
and Caco-2 permeability, which confirmed the new chemotype was promising from further 
development prospective. The relatively high plasma protein binding observed for 4k-n perhaps is 
not surprising for these highly lipophilic compounds
22
 and may not present a significant 
development obstacle provided the rate of dissociation from plasma proteins is sufficient to 
maintain the required plasma levels (vide infra). The principal weakness of the series studied herein 
was its low metabolic stability determined by incubation of compounds 4k-n in the presence of 
mouse liver microsomes. Indeed the half-life of 4l-m was around 10 minutes with unacceptably 
high clearance.  
 
Table 3. ADME profile of compounds 4k-n.  
 4k 4l 4m 4n 
Aqueous solubility (PBS, pH 7.4)
a
 (M) 143 151 42 69 
Plasma protein binding (human)
a
 (%) 98.3 98.8 99.3 99.8 
Metabolic stability (mouse liver 
microsomes) 
T1/2, min 23.4 8.5 11.8 9.6 
CLint, L/min/mg 71.3 196.0 141.1 173.3 
A-B permeability (Caco-2, cm∙s-1)b (∙10-6) 8.7 12.0 15.8 10.4 
a
 Each value is an average of n = 4, measured at c = 1 M. 
b
 Each value is an average of n = 2, measured at c = 10 M. 
The highest metabolic stability observed for compound 4k (EC50 = 0.41 M corresponding to 218 
ng/mL) among the four selected frontrunner candidates was the principal decisive point in 
nominating this compounds for pharmacokinetic characterization in mice at the dosage of 10 mg/kg 
(administered intravenously and orally).  
As can be seen from pharmacokinetic parameters presented in Table 4, compound 4k demonstrated 
satisfactory oral bioavailability (F, %) and plasma levels commensurate with or significantly higher 
than the in vitro EC50 value, on oral and intravenous administration, respectively.  
 
Table 4. Pharmacokinetic parameters determined in C57BL/6J mice (n=5 per treatment group). 
 4k i.v. (10 mg/kg) 4k p.o. (10 mg/kg) 
Tmax (min) 10 30 
Cmax (ng/mL) 2,772 226 
AUCinf_obs (min∙ng/mL) 107,519 11,055 
F (%) 10.3 
3. Conclusions 
The toxicity associated with high lipophilicity of previous FFA1 agonists has been a limiting factor 
in the progression through clinical trials. Here, we have reported on a novel series of FFA1 
(GPR40) agonists. The series was designed based on the basic amine spirocyclic periphery motif 
present in Eli Lilly’s advance FFA1 agonist LU2881835. A diverse set of 19 compounds was 
synthesized via decoration of the 3-[4-(benzyloxy)phenyl]propanoic acid core building block with a 
set of spirocyclic piperidines synthesized from Boc-protected  1-oxa-9-azaspiro[5.5]undecan-4-ol 
which, in turn, had been reported as amenable on multigram scale via Prins chemistry. The 
compounds displayed meaningful structure-activity relationships in vitro stimulating calcium flux 
in FFA1-overexpressing CHO cells and four frontrunner compounds having EC50 values in the 
0.055 – 0.41 M range have been identified. The compounds displayed an overall satisfactory 
profile except for low metabolic stability. Compound 4k having the highest mouse liver microsome 
stability and EC50 = 0.41 M was evaluated for pharmacokinetics in mice on intravenous and oral 
administration. This lead compound demonstrated high plasma levels achieved even on oral 
administration of 10 mg/kg dose and absolute oral bioavailability (F) of 10.3%. This compound 
represents a promising lead for further optimization and development of the novel class of therapies 
against type 2 diabetes mellitus. 
4. Experimental section 
4.1. General experimental 
All reactions were conducted in oven-dried glassware in atmosphere of nitrogen. Melting points 
were measured with a Buchi В-520 melting point apparatus and were not corrected. Analytical thin-
layer chromatography was carried out on Silufol UV-254 silica gel plates using appropriate 
mixtures of ethyl acetate and hexane. Compounds were visualized with short-wavelength UV light. 
1
H NMR and 
13
C NMR spectra were recorded on Bruker MSL-300 spectrometers in DMSO-D6-d6 
using TMS as an internal standard. Mass spectra were recorded using Shimadzu LCMS-2020 
system with electron-spray (ESI) ionization. All and reagents and solvents were obtained from 
commercial sources and used without purification. 
All mass-spectroscopic measurements required for determination of ADME properties were 
performed using Shimadzu VP HPLC system including vacuum degasser, gradient pumps, reverse 
phase HPLC column, column oven and autosampler. The HPLC system was coupled with tandem 
mass spectrometer API 3000 (PE Sciex). The TurboIonSpray ion source was used in both positive 
and negative ion modes. Acquisition and analysis of the data were performed using Analyst 1.5.2 
software (PE Sciex). 
4.2.  Synthetic organic chemistry 
4.2.1. Starting materials 
Boc-protected 1-oxa-9-azaspiro[5.5]undecan-4-ol (1) was synthesized as described previously.
14
 1-
oxa-9-azaspiro[5.5]undecane (12) is a commercially available compound which can, alternatively, 
be prepared by deprotection of its N-Boc version reported earlier.
14
 Aldehyde 5 is a known 
compound prepared according to the literature protocol.
15
 
4.2.1.1. Methyl 4-({4-[(1E)-3-tert-butoxy-3-oxoprop-1-en-1-yl]phenoxy}methyl)benzoate (7). 
A 500-mL round-bottomed flask was charged with a suspension of NaH (60% dispersion in mineral 
oil, 1.1 g, 28 mmol) in dry THF (250 mL) and cooled to 0 °C. Phosphonate 6 (7.6 g, 30 mmol) was 
added in portions and the resulting mixture was stirred at that temperature for 1 h. A solution of 
compound 5 (6.7 g, 25 mmol) in THF (50 mL) was added dropwise. The reaction mixture was 
heated at reflux for 30 min, cooled down to r. t. and poured into water (250 mL). The aqueous 
solution was extracted with ethyl acetate (3 x 100 mL) and the combined organic extracts were 
washed with 5% aqueous HCl, 10% aqueous potassium bicarbonate, water, dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel using 015% ethyl acetate in hexanes as eluent to provide the title compound. 
Yield 7.7 g (21 mmol, 83%); white crystals; mp = 104-107 °C; 
1
H NMR (300 MHz, CDCl3) δ 8.07 
(d, J = 8.2 Hz, 2H), 7.60 – 7.43 (m, 5H), 6.96 (d, J = 8.7 Hz, 2H), 6.26 (dd, J = 15.9, 2.5 Hz, 1H), 
5.15 (s, 2H), 3.93 (d, J = 2.4 Hz, 3H), 1.54 (s, 9H);
13
C NMR (75 MHz, DMSO) δ 166.8, 166.6, 
159.9, 143.0, 141.7, 129.9, 129.6, 127.9, 127.0, 118.1, 115.1, 80.3, 69.4, 52.2, 28.2; MS m/z  369.6  
(M + H
+
). 
4.2.1.2. Methyl 4-{[4-(3-tert-butoxy-3-oxopropyl)phenoxy]methyl}benzoate (8). 
A 500-mL autoclave chamber was charged with a solution of compound 7 (7.7 g, 21 mmol) 
anhydrous methanol (250 mL) and Raney Ni (10 g, freshly prepared suspension). A 100-atm 
pressure of hydrogen was applied and the mixture was stirred at r. t. for 10 h. Upon release of the 
hydrogen pressure and purging with nitrogen, the contents of the autoclave were filtered through a 
pad of celite, washed with methanol and the filtrate was concentrated in vacuo to provide the title 
compound. 
Yield 7.8 g (21 mmol, quantitative); white crystals, mp = 62-64 °C; 
1
H NMR (300 MHz, CDCl3) δ 
8.08 (t, J = 10.6 Hz, 2H), 7.51 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 Hz, 
2H), 5.12 (s, 2H), 3.93 (s, 3H), 2.86 (t, J = 7.7 Hz, 2H), 2.51 (t, J = 7.7 Hz, 2H), 1.43 (s, 9H); 
13
C 
NMR (75 MHz, MeOD) δ 172.3, 166.9, 156.9, 142.4, 133.5, 129.9, 129.6, 129.4, 127.0, 114.8, 
80.3, 69.4, 52.2, 37.3, 30.3, 28.1; MS m/z 371.5 (M + H
+
). 
4.2.1.3. 4-{[4-(3-Tert-butoxy-3-oxopropyl)phenoxy]methyl}benzoic acid (9). 
A 25-mL round-bottomed flask was charged with a solution of compound 8 (2.7 g, 7.29 mmol) in 
1,4-dioxane (15 mL). A solution of LiOH (170 mg, 7.29 mmol) in water (3.0 mL) was added and 
the resulting mixture was stirred at r. t. for 12 h. 1,4-Dioxane was removed in vacuo and the residue 
was dissolved in water (100 mL). The aqueous solution was extracted with ethyl acetate (3 x 50 
mL) and the organic extracts were discarded. The pH of the aqueous phase was carefully adjusted to 
5.0 with 5% aqueous HCl and the solution was again extracted with ethyl acetate (3x50 mL). The 
combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel using 05% methanol in 
chloroform. The analytically pure title compound was obtained after crystallization from toluene. 
Yield 1.8 g (5.1 mmol, 70%); white crystals, mp = 173-175 °C; 
1
H NMR (300 MHz, CDCl3) δ 8.13 
(d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7.13 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 5.13 
(s, 2H), 2.86 (t, J = 7.7 Hz, 2H), 2.51 (t, J = 7.7 Hz, 2H), 1.41 (s, 9H); 
13
C NMR (75 MHz, CDCl3) 
δ 172.4, 171.8, 156.8 143.5, 133.5, 130.5, 129.4, 128.7, 127.0, 114.8, 80.4, 69.3, 37.3, 30.3, 28.1; 
MS m/z 357.6 (M + H
+
). 
4.2.1.4. Tert-butyl 3-{4-[(4-formylbenzyl)oxy]phenyl}propanoate (1). 
A 250-mL three-necked round-bottomed flask kept under a positive pressure of nitrogen was 
charged with a solution of compound 9 (5.3 g, 15 mmol, obtained from several runs of the previous 
three steps) in anhydrous THF (100 mL) and N-methylmorpholine (1.7 g, 17 mmol). The mixture 
was cooled to -30 °C and a solution of isobutyl chloroformate (2.3 g, 17 mmol) in anhydrous THF 
(10 mL) was added dropwise. The reaction mixture temperature was allowed to reach -5 °C and the 
precipitate formed was filtered off. To the filtrate thus obtained, a suspension of sodium 
borohydride (1.1 g, 5.61 mmol) in water (10 mL) was added in portions. The resulting mixture was 
stirred for 30 min. The volatiles were removed in vacuo and the residue was partitioned between 
ethyl acetate (200 mL) and water (100 mL). The organic layer was washed with 5% aqueous HCl, 
5% aqueous potassium carbonate and brine, dried over anhydrous Na2SO4, filtered and concentrated 
in vacuo. The residue (5.0 g) was dissolved in dichloromethane (50 mL) and active MnO2 (15 g) 
was added. The resulting mixture was stirred at r. t. for 12 h, filtered through a pad of celite and the 
latter was washed with copious amounts of dichloromethane. The filtrate was concentrated in 
vacuo. The residue was purified by column chromatography on silica gel using 010% ethyl 
acetate in hexanes as eluent to provide the title compound. 
Yield 3.1 g (9.0 mmol, 60.7% over 2 steps); white crystals, mp = 57-59 °C; 
1
H NMR (300 MHz, 
DMSO) δ 10.03 (s, 1H), 7.91 (d, J = 8.1 Hz, 2H), 7.61 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 
6.90 (d, J = 8.6 Hz, 2H), 5.14 (s, 2H), 2.87 (t, J = 7.7 Hz, 2H), 2.52 (t, J = 7.7 Hz, 2H), 1.42 (s, 9H); 
13
C NMR (75 MHz, CDCl3) δ 191.9), 172.3, 156.7, 144.2, 135.9, 133.6, 130.0, 129.4, 127.5, 114.8,  
80.3, 69.2, 37.3, 30.3, 28.1; MS m/z 341.4 (M + H
+
). 
4.2.1.5. tert-Butyl 4-oxo-1-oxa-9-azaspiro[5.5]undecane-9-carboxylate (10). 
To a solution of 1 (47.0 g, 173 mmol) in dichloromethane (500 mL) PDC (130 g, 346 mmol) was 
added in small portions. The reaction mixture was stirred at r. t. for 18 h. The precipitate formed 
was filtered off and washed with dichloromethane (150 mL). The combined filtrate and washings 
were washed with 5% aqueous HCl, dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel using chloroform as eluent 
to provide the title compound. 
Yield 35.4 g (131 mmol, 76%). White crystalline solid, m. p. = 61 – 64 ºC. 1H NMR (300 MHz, 
DMSO-d6) δ 4.00 (t, J = 6.1 Hz, 2H), 3.75 (dd, J = 10.1, 3.3 Hz, 2H), 3.22 – 3.09 (m, 2H), 2.46 (t, J 
= 6.0 Hz, 2H), 2.36 (s, 2H), 1.80 (d, J = 12.9 Hz, 2H), 1.50 (dd, J = 14.6, 2.8 Hz, 2H), 1.45 (s, 9H).
 
13
C NMR (75 MHz, DMSO-d6) δ 206.8, 154.8, 79.6, 74.9, 60.4, 52.7, 41.7, 39.1, 34.4, 28.4. MS 
m/z 270.2 (M+H
+
). 
4.2.1.6. 2-(9-(tert-Butoxycarbonyl)-1-oxa-9-azaspiro[5.5]undecan-4-yl)acetic acid (11). 
To a 0 ºC, vigorously stirred suspension of NaH (6.54 g, 163 mmol, 60% dispersion in mineral oil) 
in THF (300 mL) thriethylphosphonoacetate (45 g, 200 mmol) was added dropwise under argon. 
The stirring continued at that temperature for 1 h, whereupon a solution of 10 (40 g, 149 mmol) in 
THF (100 mL) was added. The reaction mixture was allowed to reach r. t. and was stirred at that 
temperature for 18 h. The reaction mixture was poured into water (500 mL) and the aqueous phase 
was extracted with ethyl acetate (3 x 200 mL). The combined organic extracts wer washed with 3% 
aqueous citric acid, 5% aqueous NaHCO3, brine, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The residue was fractionated on silica gel using 05% ethyl acetate in 
hexanes as eluent. The fractions containing the olefination product (according to LC MS analysis) 
were pooled and concentrated to dryness (yielding 32.7 g of the material). The residue (10.9 g) was 
dissolved in EtOH (200 mL), HCOONH4 (2.8 g, 0.44 mmol) and 10% Pd on carbon (300 mg) were 
added and the resulting mixture was heated at reflux for 12 h. The mixture was cooled to r. t. and 
filtered through a plug of Celite (subsequently washing the latter with EtOH). The combined filtrate 
and washings were concentrated to dryness. The residue was partitioned between water (150 mL) 
and ethyl acetate (150 mL). The organic layer was separated and the aqueous layer was additionally 
extracted with ethyl acetate (2 x 150 mL). The combined organic extracts were washed with 3% 
aqueous citric acid, 5% aqueous NaHCO3 and brine, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The residue was dissolved in MeOH (100 mL) and a solution of KOH (5.42 
g, 96.7 mmol) in water (20 mL) was added. The mixture was stirred at r. t. for 18 h and 
concentrated to dryness in vacuo. The residue was dissolved in water (100 mL), the aqueous 
solution was extracted with ether (2 x 50 mL) and then acidified to pH 5.0 with 3% aqueous HCl. 
The solution thus obtained was extracted with ethyl acetate (3 x 100 mL) and the combined organic 
extracts were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo 
to provide analytically pure 11. 
Yield 7.35 g (49%). 
1
H NMR (300 MHz, DMSO-d6) δ 12.03 (s, 1H), 3.67 – 3.45 (m, 4H), 3.16 – 
2.83 (m, 2H), 2.16 – 1.95 (m, 4H), 1.63 – 1.51 (m, 2H), 1.49 – 1.30 (m, 2H), 1.38 (s, 9H), 1.28 – 
0.89 (m, 3H). 
13
C NMR (75 MHz, DMSO-d6) δ 173.2, 153.9, 78.4, 69.7, 59.7, 41.6, 41.1, 38.6, 
32.0, 28.7, 28.1, 26.8. MS m/z 314.5 (M+H
+
). 
4.2.2. General procedure for the preparation of compounds 3a-g. 
A solution of tert-butyl 1-oxa-9-azaspiro[5.5]undecan-4-ol (4g, 14.8 mmol) in DMF (20 mL) was 
added dropwise to a 0 ºC suspension of NaH (1.3 g, 32.6 mmol, 60% dispersion in mineral oil) in 
dry DMF (100 mL) under argon. The resulting mixture was stirred at 0 ºC for 30 min whereupon a 
solution of the respective alkyl halide - MeI, EtBr, cyclo-PrCH2Br or ArCH2Cl (19.2 mmol) – in 
DMF (10 mL) was added dropwise. The resulting mixture was allowed to warm up to r. t. and 
stirred at that temperature for 18 h. The reaction mixture was poured into water (200 mL) and the 
aqueous phase was extracted with ethyl acetate (3 x 200 mL). The combined organic extracts were 
washed with 3% aqueous citric acid, 5% aqueous NaHCO3, brine and water, dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. The residue was fractionated on silica gel using 0 5% 
ethyl acetate in hexanes as eluent and the fractions containing the desired product (according to LC 
MS analysis) were combined and concentrated in dryness. Without further purification, the residue 
was dissolved in CH2Cl2 (3 mL/mmol calculated assuming 100% purity of the material obtained in 
the previous step), the solution was cooled to 0 ºC and TFA (1 mL/mmol) was added. The mixture 
thus obtained was stirred at 0 ºC for 6 h and then concentrated to dryness to provide, after 
crystallization from isopropyl alcohol, the target spirocyclic piperidine as a trifluoroacetate salt. 
Compounds 3a-b were converted to hydrochloride salts by treatment of their r. t. solutions in 1,4-
dioxane with 4M HCl in 1,4-dioxane followed by stirring for 3 h, evaporation of the volatiles in 
vacuo and crystallization from isopropyl alcohol. 
4.2.2.1. 4-Methoxy-1-oxa-9-azaspiro[5.5]undecane hydrochloride (3a).  
Yield 1.16 g (75%). White crystals, m. p. = 188 – 191 ºC. 1H NMR (300 MHz, DMSO-d6) δ 9.02 (s, 
1H), 8.98 (s, 1H), 3.78 – 3.67 (m, 1H), 3.55 – 3.35 (m, 2H), 3.23 (s, 3H), 3.06 – 2.76 (m, 4H), 2.11 
– 2.02 (m, 1H), 1.91 – 1.55 (m, 5H), 1.38 – 1.16 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 71.9, 
69.1, 58.3, 54.8, 40.4, 38.8, 33.5, 31.3, 28.0. MS m/z 185.9 (M+H
+
). 
4.2.2.2. 4-Ethoxy-1-oxa-9-azaspiro[5.5]undecane hydrochloride (3b). 
Yield 991 mg (63%). White crystals, m. p. = 191 – 193 ºC. 1H NMR (300 MHz, DMSO-d6) δ 9.04 
(s, 1H), 8.94 (s, 1H), 3.76 – 3.55 (m, 2H), 3.54 - 3.49 (m, 1H), 3.44 (q, J = 7.00 Hz, 2H), 3.08 – 
2.75 (m, 4H), 2.13 – 2.01 (m, 1H), 1.89 – 1.55 (m, 5H), 1.39 – 1.15 (m, 2H), 1.08 (t, J = 7.00 Hz, 
3H). 
13
C NMR (75 MHz, DMSO-d6) δ 70.2, 69.1, 62.2, 58.4, 40.9, 38.8, 33.5, 31.9, 28.0, 15.6. MS 
m/z 199.8 (M+H
+
). 
4.2.2.3. 4-(Cyclopropylmethoxy)-1-oxa-9-azaspiro[5.5]undecane trifluoroacetate (3c). 
Yield 1.29 g (62%). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 8.55 (s, 1H), 8.45 (s, 
1H), 3.78 – 3.57 (m, 2H), 3.54 – 3.43 (m, 1H), 3.29 – 3.18 (m, 2H), 3.14 – 2.79 (m, 4H), 2.19 – 
1.48 (m, 6H), 1.40 – 1.20 (m, 2H), 1.01 – 0.88 (m, 1H), 0.48 – 0.38 (m, 2H), 0.17 – 0.09 (m, 2H). 
13
C NMR (75 MHz, DMSO-d6) δ 71.5, 70.2, 69.1, 58.5, 40.9, 39.1, 33.7, 32.0, 28.2, 11.0, 3.0, 2.9. 
MS m/z 226.3 (M+H
+
). 
4.2.2.4. 4-[(3-Fluorobenzyl)oxy]-1-oxa-9-azaspiro[5.5]undecane (3d). 
This compound was converted to free base by partitioning between sat. aq. NaHCO3 and ethyl 
acetate, followed by separation of ethyl acetate solution, drying over anhydrous Na2SO4, filtration, 
concentration in vacuo and flash chromatography on silica gel using 20% MeOH in CH2Cl2. Yield 
940 mg (45%). 
1
H NMR (300 MHz, CDCl3) δ 7.32 – 7.27 (m, 1H), 7.09 – 6.92 (m, 3H), 4.51 (s, 
2H), 3.88 – 3.80 (m, 1H), 3.75 – 3.66 (m, 1H), 3.59 – 3.49 (m, 1H), 3.39 – 2.98 (m, 4H), 2.07 – 
1.40 (m, 8H). 
13C NMR (75 MHz, CDCl3) δ 162.9 (d, J = 245.8 Hz), 141.0 (d, J = 7.1 Hz), 129.9 
(d, J = 8.1 Hz), 122.7 (d, J = 2.8 Hz), 114.4 (d, J = 24.1 Hz), 114.1 (d, J = 24.4 Hz), 77.2, 71.1, 
69.9, 58.6, 41.1, 40.2, 40.0, 34.8, 31.7. MS m/z 279.9 (M+H
+
). 
4.2.2.5. 4-{[4-(Trifluoromethyl)benzyl]oxy}-1-oxa-9-azaspiro[5.5]undecane trifluoroacetate 
(3e). 
Yield 1.40 g (68%). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 8.49 (s, 2H), 7.68 (d, J = 
8.09 Hz, 2H), 7.53 (d, J = 8.00 Hz, 2H), 4,60 (s, 2H) , 3.79 – 3.72 (m, 2H), 3.55 – 3.47 (m, 1H), 
3.10 – 2.82 (m, 4H), 2.08 – 2.02 (m, 1H), 1.93 – 1.31 (m, 7H). 13C NMR (75 MHz, DMSO-d6) δ 
144.0, 128.0 (q, J = 31.8 Hz), 127.7, 125.2 (q, J = 3.63 Hz), 124.4 (q, J = 271.8 Hz), 70.9, 69.2, 
68.1, 58.4, 40.8, 39.1, 33.6, 31.8, 28.4. MS m/z 330.2 (M+H
+
). 
4.2.2.6. 4-(Benzyloxy)-1-oxa-9-azaspiro[5.5]undecane (3f).  
This compound was converted to free base by partitioning between sat. aq. NaHCO3 and ethyl 
acetate, followed by separation of ethyl acetate solution, drying over anhydrous Na2SO4, filtration, 
concentration in vacuo and flash chromatography on silica gel using 20% MeOH in CH2Cl2. Yield 
1.50 g (75%). 
1
H NMR (300 MHz, DMSO-d6) δ 7.39 – 7.25 (m, 5H), 4.56 – 4.46 (m, 2H), 3.80 – 
3.69 (m, 2H), 3.57 – 3.46 (m, 1H), 3.10 – 2.80 (m, 4H), 2.07 – 1.97 (m, J = 14.7 Hz, 1H), 1.96 – 
1.80 (m, 3H), 1.74 – 1.26 (m, 4H). 13C NMR (75 MHz, DMSO-d6) δ 138.9, 128.2, 127.4, 127.3, 
70.4, 69.3, 68.9, 58.3, 40.8, 39.3, 33.9, 31.8, 28.6. MS m/z 262.0 (M+H
+
). 
4.2.2.7. 4-[(4-fluorobenzyl)oxy]-1-oxa-9-azaspiro[5.5]undecane trifluoroacetate (3g). 
Yield 930 mg (45%). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 8.57 (s, 1H), 8.38(s, 
1H), 7.39 – 7.33 (m, 2H), 7.18 – 7.12 (m, 2H), 4.48 (s, 2H), 3.78 – 3.70 (m, 2H), 3.56 – 3.45 (m, 
1H), 3.11 – 2.82 (m, 4H), 2.09 – 2.01 (m, 1H), 1.92 – 1.82 (m, 3H), 1.72 – 1.36 (m, 4H).  13C NMR 
(75 MHz, DMSO-d6) δ 161.5 (d, J = 242.9 Hz), 135.2 (d, J = 2.8 Hz), 129.5 (d, J = 8.1 Hz), 114.0 
(d, J = 21.3 Hz), 70.5, 69.1, 68.2, 58.4, 40.8, 39.1, 33.6, 31.8, 28.3. MS m/z 279.8 (M+H
+
). 
4.2.3. General procedure for the preparation of compounds 3h-o. 
n-BuLi (2.5M in hexane, 4 mL, 10.0 mmol) was added dropwise under argon to a 0 ºC suspension 
of the respective alkylphosphonium chloride (10.0 mmol) in THF (50 mL). The mixture was stirred 
for 30 min whereupon a solution of 10 (2.42 g, 9.0 mmol) in THF (10 mL) was added. The reaction 
mixture was allowed to warn up to r. t. and stirred at that temperature for 18 h. At that point, sat. aq. 
NH4Cl (25 mL) was added and the mixture was diluted with ethyl acetate (50 mL) and water (20 
mL). Organic phase was separated and the aqueous phase was additionally extracted with ethyl 
acetate (2 x 50 mL). The combined organic extracts were washed with brine, dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. The residue was fractionated on silica gel using 05% 
ethyl acetate in hexanes as eluent. Fractions containing the olefination product (according to LC MS 
analysis) were pooled and concentrated to dryness. The material thus obtained was used in the 
subsequent steps without further purification. 
To a solution of this material in EtOH (20 mL/mmol assuming 100% purity of the product in the 
previous step) HCOONH4 (4 mmol/mmol) and 10% Pd on carbon (37 mg/mmol) were added and 
the resulting mixture was heated at reflux for 12 h. The mixture was cooled to r. t. and filtered 
through a plug of Celite (subsequently washing the latter with EtOH). The combined filtrate and 
washings were concentrate to dryness. The residue was partitioned between water (50 mL) and 
ethyl acetate (50 mL). The organic layer was separated and the aqueous layer was additionally 
extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with 3% 
aqueous citric acid, 5% aqueous NaHCO3 and brine, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. Without further purification, the residue was dissolved in CH2Cl2 (3 
mL/mmol calculated assuming 100% purity of the material obtained in the previous step), the 
solution was cooled to 0 ºC and TFA (1 mL/mmol) was added. The mixture thus obtained was 
stirred at 0 ºC for 6 h and then concentrated to dryness to provide, after crystallization from 
isopropyl alcohol, the target spirocyclic piperidine as a trifluoroacetate salt. Compounds 3h, 3j, 3m-
n were converted to hydrochloride salts by treatment of their r. t. solutions in 1,4-dioxane with 4M 
HCl in 1,4-dioxane followed by stirring for 3 h, evaporation of the volatiles in vacuo and 
crystallization from isopropyl alcohol. 
4.2.3.1. 4-Methyl-1-oxa-9-azaspiro[5.5]undecane hydrochloride (3h). 
Yield 342 mg (45%). White crystalline solid, m. p. = 223 – 226 ºC. 1H NMR (300 MHz, DMSO-d6) 
δ 9.07 (s, 1H), 9.03 (s, 1H) 3.71 – 3.45 (m, 2H), 3.06 – 2.90 (m, 3H), 2.87 – 2.72 (m, 1H), 2.36 – 
2.26 (m, 1H), 1.80 – 1.70 (m, 2H), 1.59 – 1.45 (m, 4H), 1.11 – 0.90 (m, 2H), 0.85 (d, J = 6.41 Hz, 
3H). 
13
C NMR (75 MHz, DMSO-d6) δ 68.2, 60.2, 43.8, 35.2, 34.1, 25.4, 24.3, 22.3. MS m/z 170.0 
(M+H
+
). 
4.2.3.2. 4-[4-(Trifluoromethyl)benzyl]-1-oxa-9-azaspiro[5.5]undecane trifluoroacetate (3i). 
Yield 1 g (38%). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.30 (s, 1H), 
7.65 (d, J = 8.00 Hz, 2H), 7.42 (d, J = 7.92 Hz, 2H), 3.68 – 3.61 (m, 1H), 3.48 – 3.40 (m, 1H), 3.09 
– 2.77 (m, 4H), 2.64 – 2.51 (m, 2H), 2,36 – 2.32 (m, 1H), 2.03 – 1.92 (m, 1H), 1.70 – 1.02 (m, 7H). 
13
C NMR (75 MHz, DMSO-d6) δ 144.8, 129.8, 126.7 (q, J = 31.6 Hz), 125.0 (q, J = 3.81 Hz), 
122.6, 79.2, 68.1, 60.0, 42.2, 41.7, 35.3, 31.7, 31.1, 25.5. MS m/z 314.0 (M+H
+
). 
4.2.3.3. 4-(3-Fluorobenzyl)-1-oxa-9-azaspiro[5.5]undecane hydrochloride (3j) 
Yield 1.03 g (65%). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.31 (s, 
1H), 7.36 – 7.24 (m, 1H), 7.06 – 6.97 (m, 3H), 3.68 – 3.60 (m, 1H), 3.48 – 3.39 (m, 1H), 3.08 –  
2.75 (m, 4H), 2.49 – 2.41 (m, 2H), 2.36 – 2.31 (m, 1H), 2.02 – 1.88 (m, 1H), 1.70 – 1.27 (m, 5H), 
1.18 – 0.98 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 162.2 (d, J = 242.9 Hz), 142.7 (d, J = 7.4 
Hz), 130.0 (d, J = 8.3 Hz), 125.2, 115.6 (d, J = 20.5 Hz), 112.7 (d, J = 20.7 Hz), 68.1, 60.0, 42.2, 
41.8, 35.3, 31.7, 31.0, 25.5. MS m/z 264.6 (M+H
+
). 
4.2.3.4. 4-(4-Fluorobenzyl)-1-oxa-9-azaspiro[5.5]undecane trifluoroacetate (3k) 
Yield 1.02 g (81%). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.30 (s, 
1H), 7.22 – 7.16 (m, 2H), 7.08 (t, J = 8.87 Hz, 2H), 3.66 – 3.60 (m, 1H), 3.47 – 3.38 (m, 1H), 3.09 – 
2.98 (m, 3H), 2.89 – 2.75 (m, 1H), 2.44 (t, J = 7.23 Hz, 2H), 2.36 – 2.29 (m, 1H), 1.97 – 1.85 (m, 
1H), 1.71 – 1.29 (m, 5H), 1.18 – 0.97 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 160.8 (d, J = 241.1 
Hz), 135.8 (d, J = 3.1 Hz), 130.7 (d, J = 7.7 Hz), 114.9 (d, J = 20.7 Hz), 68.2, 60.1, 41.8, 41.8, 35.4, 
31.8, 31.4, 25.6. MS m/z 264.1 (M+H
+
). 
4.2.3.5. 4-Benzyl-1-oxa-9-azaspiro[5.5]undecane trifluoroacetate (3l) 
Yield 1.03 g (74%). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 8.51 (s, 1H), 8.28 (s, 
1H), 7.32 – 7.13 (m, 5H), 3.64 (dd, J = 11.75, 4.32 Hz, 1H), 3.43 (t, J = 11.30 Hz, 1H), 3.11 – 2.73 
(m, 4H), 2.45 (t, J = 6.55 Hz, 2H), 2.38 – 2.29 (m, J = 14.72 Hz, 1H), 2.01 – 1.84 (m, 1H), 1.70 – 
1.23 (m, 5H), 1.18 – 0.97 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 139.7, 129.0, 128.2, 125.9, 
68.1, 60.1, 42.7, 41.9, 35.4, 31.9, 31.3, 25.5. MS m/z 246.2 (M+H
+
). 
4.2.3.6. 4-(4-Methoxybenzyl)-1-oxa-9-azaspiro[5.5]undecane-9 hydrochloride (3m) 
Yield 660 mg (62%). White crystalline solid, m. p. = 208 – 216 ºC. 1H NMR (300 MHz, DMSO-d6) 
δ 9.15 (s, 2H), 7.07 (d, J = 8.53 Hz, 2H), 6.83 (d, J = 8.54 Hz, 2H), 3.71 (s, 3H), 3.63 (dd, J = 
11.73, 4.32 Hz, 1H), 3.49 – 3.37 (m, 1H), 3.04 – 2.70 (m, 4H), 2.39 (d, J = 6.94 Hz, 2H), 2.35 – 
2.25 (m, 1H), 1.95 – 1.67 (m, 2H), 1.59 – 1.36 (m, 4H), 1.18 – 0.92 (m, 2H). 13C NMR (75 MHz, 
DMSO-d6) δ 157.4, 131.4, 129.8, 113.5, 68.1, 60.0, 54.8, 41.7, 38.8, 38.7, 35.1, 31.9, 31.3, 25.2. 
MS m/z 275.8 (M+H
+
). 
4.2.3.7. 4-(4-Methylbenzyl)-1-oxa-9-azaspiro[5.5]undecane hydrochloride (3n) 
Yield 700 mg (53%). White crystalline solid, m. p. = 194 – 197 ºC. 1H NMR (300 MHz, DMSO-d6) 
δ 9.04 (s, 2H), 7.06 (q, J = 8.10 Hz, 4H), 3.64 (dd, J = 11.78, 4.33 Hz, 1H), 3.49 – 3.38 (m, 1H), 
3.05 – 2.70 (m, 4H), 2.41 (d, J = 6.97 Hz, 2H), 2.26 (s, 3H), 1.97 – 1.83 (m, 1H), 1.80 – 1.35 (m, 
6H), 1.18 – 0.93 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 136.4, 134.6, 128.7, 128.6, 68.1, 60.0, 
42.2, 41.8, 38.8, 35.1, 31.9, 31.2, 25.3, 20.5. MS m/z 260.5 (M+H
+
). 
4.2.3.8. 4-(2-fluorobenzyl)-1-oxa-9-azaspiro[5.5]undecane-9 trifluoroacetate (3o) 
Yield 1.02 g (80%). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 8.47 (s, 1H), 8.25 (s, 
1H), 7.29 – 7.22 (m, 2H), 7.17 – 7.10 (m, 2H), 3.69 – 3.61 (m, 1H), 3.48 – 3.39 (m, 1H), 3.08 – 
2.98 (m, 3H), 2.87 – 2.74 (m, 1H), 2.54 – 2.51 (m, 2H), 2.38– 2.27 (m, 1H), 1.98 – 1.87 (m, 1H), 
1.67 – 1.27 (m, 5H), 1.18 – 1.02 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 160.6 (d, J = 242.7 Hz), 
131.7 (d, J = 4.8 Hz), 128.1 (d, J = 8.1 Hz), 126.2 (d, J = 16.1 Hz), 124.2 (d, J = 3.5 Hz), 115.1 (d, J 
= 22.3 Hz), 68.1, 60.0, 41.8, 35.5, 35.3, 31.8, 30.4, 25.5. MS m/z 263.9 (M+H
+
). 
4.2.4. General procedure for the preparation of compounds 3p-r. 
Isobutyl chloroformate (0.44 g, 3.19 mmol) was added dropwise under argon to a -30 ºC solution of 
11 (1g, 3.19 mmol) and N-methylmorpholine (0.39 g, 3.83 mmol) in THF (40 mL). After a brief (30 
min) stirring, a solution of the respective amidoxime (3.83 mmol) in THF (10 mL) was added 
dropwise. The reaction mixture was allowed to reach r. t., stirred at that temperature for 12 h, 
filtered and concentrated in vacuo. The residue was dissolved in toluene (50 mL), TBAF (0.1 g) 
was added and the mixture was heated at reflux for 5 h with azeotropic removal of water using a 
Dean-Stark trap. The toluene solution was washed with water, 1% aqueous citric acid, 5% sat. 
aqueous NaHCO3, brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness in 
vacuo. The residue was fractionated on silica gel using chloroform as eluent. The fractions 
containing the 1,2,4-oxadiazole product (according to LC MS analysis) were pooled and 
concentrated in vacuo. The residue was dissolved in 1,4-dioxane (15 mL) and treated with 4M HCl 
in 1,4-dioxane (1 mL). After stirring at r. t. for 6 h, the reaction mixture was concentrated to dryness 
in vacuo and the residue was crystallized from isopropyl alcohol to provide analytically pure title 
compound. 
4.2.4.1. 4-[(3-Pyridin-3-yl-1,2,4-oxadiazol-5-yl)methyl]-1-oxa-9-azaspiro[5.5]undecane 
dihydrochloride (3p) 
Yield 350 mg (63%). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 10.31 (s, 2H), 9.27 (s, 
1H), 8.93 (d, J = 5.09 Hz, 1H), 8.66 (d, J = 7.70 Hz, 1H), 7.89 (dd, J = 7.73, 5.37 Hz, 1H), 7.28 – 
7.09 (m, 1H), 3.69 (dd, J = 11.89, 4.41 Hz, 1H), 3.53 (t, J = 11.57 Hz, 1H), 3.07 – 2.73 (m, 6H), 
2.42 – 2.26 (m, 2H), 1.88 – 1.51 (m, 5H), 1.35 – 1.11 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 
179.7, 165.0, 148.7, 144.4, 138.4, 126.0, 123.9, 68.3, 59.7, 41.0, 38.8, 35.0, 32.5, 31.4, 28.4. MS 
m/z 315.4 (M+H
+
). 
4.2.4.2. 4-[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-1-oxa-9-azaspiro[5.5]undecane 
hydrochloride (3q) 
Yield 350 mg (59%). White crystalline solid, m. p. = 179 – 187 ºC. 1H NMR (300 MHz, DMSO-d6) 
δ 9.17 (s, 2H), 3.71 – 3.62 (m, 1H), 3.54 – 3.45 (m, 1H), 3.08 – 2.95 (m, 3H), 2.88 – 2.73 (m, 3H), 
2.38 – 2.32 (m, 1H), 2,21– 2,03 (m, 2H), 1.82 – 1.45 (m, 5H), 1.24 – 1.01 (m, 4H), 0,88 – 0.83 (m, 
2H). 
13
C NMR (75 MHz, DMSO-d6) δ 178.3, 172.1, 68.7, 60.2, 41.5, 35.5, 32.9, 31.8, 28.7, 25.7, 
7.8, 6.7. MS m/z 278.5 (M+H
+
). 
4.2.4.3. 4-[(3-(2-methoxyethyl)-1,2,4-oxadiazol-5-yl)methyl]-1-oxa-9-azaspiro[5.5]undecane 
hydrochloride (3r) 
Yield 330 mg (55%). White crystalline solid, m. p. = 132 – 135 ºC. 1H NMR (300 MHz, DMSO-d6) 
δ 9.18 (s, 2H), 3.70 – 3.63 (m, 3H), 3.55 – 3.47 (m, 1H), 3.22 (s, 3H), 3.05 – 2.87 (m, 6H), 2.83 (d, 
J = 6.91 Hz, 2H), 2.39 - 2.32 (m, 1H), 2.26 – 2.15 (m, 1H), 1.82 – 1.72 (m, 1H), 1.58 – 1.53 (m, 
4H), 1.23 – 1.07 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 177.9, 168.0, 68.4, 68.2, 59.7, 57.8, 
41.0, 38.8, 35.0, 32.3, 31.3, 28.2, 26.0, 25.2. MS m/z 296.3 (M+H
+
). 
4.2.5. General procedure for the preparation of compounds 4a-s. 
A solution of the respective spirocyclic piperidine salt 3a-r or 12 (0.46 mmol) in CH2Cl2 (5 mL) 
was treated with trimethylamine (n x 0.46 mmol, where n = number of salt parts per molecule) 
followed by a solution of 2 (0.44 mmol) in CH2Cl2 (5 mL). After a brief stirring (15 min), sodium 
triacetoxyboohydride (STAB, 1.32 mmol) was added and the stirring continued for 12 h at r. t. The 
reaction was poured into 10% aqueous NaHCO3 (20 mL). Organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (2 x 10 mL). The combined organic extracts were washed 
with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was 
fractionated on silica gel using 01% MeOH in CH2Cl2. The fractions containing the reductive 
amination product (according to LC MS analysis) were pooled and concentrated in vacuo. The 
residue was dissolved in CH2Cl2 (3 mL) and treated with TFA (1 mL). The mixture was stirred at r. 
t. for 18 h and concentrated in vacuo. 2M HCl in ether (3 mL) was added to the residue and the later 
was triturated (with occasional sonication) until a crystalline hydrochloride salt formed. The latter 
was separated by filtration, washed with ether and dried in vacuo to provide analytically pure 
compounds 4a-s. 
4.2.5.1. 3-[4-({4-[(4-Methyl-1-oxa-9-azaspiro[5.5]undec-9-yl)methyl]benzyl}oxy)phenyl] 
propanoic acid hydrochloride (4a).  
Yield 26.3 mg (0.06 mmol, 13.6 %). White crystalline solid, m. p. = 183 – 187 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.49 (s, 1H), 7.69 (d, J = 7.8 Hz, 2H), 7.47 (d, J = 7.7 Hz, 2H), 7.12 (d, J = 8.2 
Hz, 2H), 6.92 (d, J = 8.3 Hz, 2H), 5.08 (s, 2H), 4.40 – 4.22 (m, 2H), 3.53 – 3.43 (m, 4H), 3.11 – 
3.01 (m, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.57 (t, J = 7.4 Hz, 2H), 2.46 – 2.37 (m, 1H), 2.13 – 1.88 (m, 
2H), 1.81 – 1.68 (m, 2H), 1.59 – 1.34 (m, 2H), 129 1.11 – 0.81 (m, 5H). 13C NMR (75 MHz, 
DMSO-d6) δ 172.7, 156.6, 138.4, 132.7, 131.6, 129.4, 129.2, 127.7, 114.6, 68.7, 67.9, 60.2, 58.2, 
51.2, 46.9, 43.9, 35.1, 34.0, 29.4, 25.4, 24.4, 22.2. HRMS (ESI) m/z calcd for C27H35NO4 [M+H
+
] 
438.2644, found 438.2598. 
4.2.5.2. 3-[4-({4-[(4-Ethoxy-1-oxa-9-azaspiro[5.5]undec-9-
yl)methyl]benzyl}oxy)phenyl]propanoic acid hydrochloride (4b). 
Yield 73 mg (0.16 mmol, 35.5 %). White crystalline solid, m. p. = 182 – 186 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.48 (s, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.47 (d, J = 7.8 Hz, 2H), 7.13 (d, J = 8.4 
Hz, 2H), 6.91 (d, J = 8.4 Hz, 2H), 5.08 (s, 2H), 4.41 – 4.20 (m, 2H), 3.75 – 3.56 (m, 2H), 3.52 - 
3.47 (m, 1H), 3.42 (dd, J = 14.0, 7.0 Hz, 2H), 3.10 – 2.83 (m, 4H), 2.74 (t, J = 7.4 Hz, 2H), 2.47 (t, 
J = 7.7 Hz, 2H), 2.19 - 1.62 (m, 6H), 1.38 – 1.18 (m, 2H), 1.07 (t, J = 7.0 Hz, 3H). 13C NMR (75 
MHz, DMSO-d6) δ 173.7, 156.5, 138.4, 133.1, 131.6, 129.3, 129.2, 127.7, 114.5, 70.2, 68.7, 68.6, 
62.1, 58.3, 58.2, 46.8, 46.6, 41.0, 35.6, 33.5, 31.9, 29.5, 28.0, 15.5. HRMS (ESI) m/z calcd for 
C28H37NO5 [M+H
+
] 468.2750, found 468.2754. 
4.2.5.3. 3-{4-[(4-{[4-(Cyclopropylmethoxy)-1-oxa-9-azaspiro[5.5]undec-9-
yl]methyl}benzyl)oxy]phenyl}propanoic acid hydrochloride (4c) 
Yield 30 mg (0.06 mmol, 13.9 %). Hygroscopic solid. 1H NMR (300 MHz, DMSO-d6) δ 11.47 (s, 
1H), 7.69 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 7.9 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.4 Hz, 
2H), 5.08 (s, 2H), 4.40 – 4.20 (m, 2H), 3.73 – 3.58 (m, 2H), 3.53 – 3.44 (m, 1H), 3.25 (dd, J = 14.7, 
6.6 Hz, 2H), 3.11 – 2.84 (m, 4H), 2.76 (q, J = 7.9 Hz, 2H), 2.57 (t, J = 7.5 Hz, 2H), 2.19 – 1.54 (m, 
6H), 1.39 – 1.16 (m, 2H), 1.01 – 0.87 (m, 1H), 0.42 (d, J = 7.6 Hz, 2H), 0.13 (d, J = 4.7 Hz, 2H). 
13
C NMR (75 MHz, DMSO-d6) δ 173.7, 156.6, 138.4, 133.1, 132.7, 131.6, 129.3, 129.2, 127.7, 
114.6, 71.4, 70.1, 68.7, 58.3, 58.2, 51.2, 46.8, 46.6, 35.6, 35.1, 33.5, 31.9, 29.4, 28.1, 10.8, 2.9, 2.8. 
HRMS (ESI) m/z calcd for C30H39NO5 [M+H
+
] 494.2906, found 494.2901. 
4.2.5.3. 3-(4-{[4-({4-[(3-Fluorobenzyl)oxy]-1-oxa-9-azaspiro[5.5]undec-9-
yl}methyl)benzyl]oxy}phenyl)propanoic acid hydrochloride (4d) 
Yield 90 mg (0.165 mmol, 37.5 %). White crystalline solid, m. p. = 187 – 190 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 10.87 (s, 1H), 7.63 (d, J = 8.05 Hz, 2H), 7.49 (d, J = 7.96 Hz, 2H), 7.40 – 7.33 
(m, 1H), 7.16 – 7.05 (m, 5H), 6.92 (d, J = 8.60 Hz, 2H), 5.09 (s, 2H), 4.56 – 4.51 (m, 2H), 4.39 – 
4.25 (m, 2H), 3.76 – 3.69 (m, 1H), 3.58 – 3.35 (m, 2H), 3.16 – 2.83 (m, 4H), 2.74 (t, J = 7.59 Hz, 
2H), 2.48 (t, J = 7.59 Hz, 2H), 2.17 – 2.10 (m, 1H), 1.95 – 1.75 (m, 5H), 1.49 – 1.31 (m, 2H). 13C 
NMR (75 MHz, DMSO-d6) δ 173.8, 162.1 (d, J = 243.2 Hz), 165.5, 142.0 (d, J = 7.1 Hz), 138.5, 
133.1, 131.59, 130.2 (d, J = 8.3 Hz), 129.3, 129.2, 127.8, 123.0 (d, J = 2.7 Hz), 114.6, 113.9 (d, J = 
20.9 Hz), 113.7 (d, J = 21.4 Hz), 70.6, 68.7, 68.6, 68.0, 58.4, 58.3, 46.9, 46.8, 35.5, 33.5, 31.6, 30.7, 
29.5, 28.3. HRMS (ESI) m/z calcd for C33H38FNO5 [M+H
+
] 548.2812, found 548.2806. 
4.2.5.4. 3-[4-({4-[(4-{[4-(Trifluoromethyl)benzyl]oxy}-1-oxa-9-azaspiro[5.5]undec-9-
yl)methyl]benzyl}oxy)phenyl]propanoic acid hydrochloride (4e)  
Yield 59 mg (0.09 mmol, 21.5 %). White crystalline solid, m. p. = 128 – 131 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 10.95 (s, 1H), 7.71– 7.62 (m, 4H), 7.55– 7.47 (m, 4H), 7.13 (d, J = 8.56 Hz, 
2H), 6.92 (d, J = 8.65 Hz, 2H), 5.08 (s, 2H) , 4.65– 4.60 (m, 2H), 4.37– 4.25 (m, 2H), 3.78 – 3.72 
(m, 2H), 3.54 – 3.46 (m, 1H), 3.15 – 2.86 (m, 4H), 2.74 (t, J = 7.55 Hz, 2H), 2.48 (t, J = 7.55 Hz, 
2H), 2.19 – 2.11 (m, 1H), 2.01 – 1.78 (m, 5H), 1.49 – 1.31 (m, 2H). 13C NMR (75 MHz, DMSO-d6) 
δ 173.8, 156.5, 143.0, 138.5, 133.1, 131.6, 129.3, 129.2, 127.9 (q, J = 13.8 Hz), 127.8, 127.6, 125.1 
(q, J = 3.8 Hz), 124.3 (q, J = 271.9 Hz), 114.5, 70.8, 68.7, 68.6, 68.0, 58.3, 58.3, 46.9, 46.8, 40.8, 
35.5, 33.5, 31.6, 29.5, 28.3 HRMS (ESI) m/z calcd for C34H38F3NO5 [M+H
+
] 598.2780, found 
598.2798. 
4.2.5.5. 3-{4-[(4-{[4-(Benzyloxy)-1-oxa-9-azaspiro[5.5]undec-9-
yl]methyl}benzyl)oxy]phenyl}propanoic acid hydrochloride (4f) 
Yield 13 mg (0.026 mmol, 5.9 %). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 11.47 (s, 
1H), 7.68 (d, J = 7.8 Hz, 2H), 7.47 (d, J = 7.7 Hz, 2H), 7.35 – 7.24 (m, 5H), 7.13 (d, J = 8.2 Hz, 
2H), 6.91 (d, J = 8.2 Hz, 2H), 5.08 (s, 2H), 4.51 (d, J = 14.0 Hz, 2H), 4.41 – 4.21 (m, 2H), 3.75 – 
3.65 (m, 2H), 3.50 – 3.45 (m, 1H), 3.10 – 2.82 (m, 4H), 2.74 (t, J = 7.4 Hz, 2H), 2.46 (t, J = 7.3 Hz, 
2H), 2.17 – 1.71 (m, 6H), 1.36 (dd, J = 23.6, 13.6 Hz, 2H). 13C NMR (75 MHz, DMSO-d6) δ 173.7, 
156.5, 138.8, 138.4, 133.1, 131.6, 129.2, 128.2, 128.1, 127.7, 127.2, 114.5, 72.1, 70.4, 68.8, 68.6, 
60.1, 58.2, 46.8, 46.6, 40.8, 35.5, 33.3, 31.6, 29.4, 28.2. HRMS (ESI) m/z calcd for C33H39NO5 
[M+H
+
] 530.2906, found 530.2916. 
4.2.5.6. 3-(4-{[4-({4-[(4-Fluorobenzyl)oxy]-1-oxa-9-azaspiro[5.5]undec-9-
yl}methyl)benzyl]oxy}phenyl)propanoic acid hydrochloride (4g)  
Yield 20 mg (0.038 mmol, 8.6 %). White crystalline solid, m. p. = 71 – 78 ºC. 1H NMR (300 MHz, 
DMSO-d6) δ 11.49 (s, 1H), 7.71 – 7.67 (m, 2H), 7.49 – 7.45 (m, 2H), 7.37 – 7.32 (m, 2H), 7.17 – 
7.11 (m, 4H), 6.91 (d, J = 8.14 Hz, 2H), 5.07 (s, 2H), 4.52 – 4.47 (m, 2H), 4.39– 4.24 (m, 2H), 3.78 
– 3.64 (m, 2H), 3.52 – 3.42 (m, 1H), 3.11 – 2.82 (m, 4H), 2.73 (t, J = 7.55 Hz, 2H), 2.48 (t, J = 7.55 
Hz, 2H), 2.17 – 1.71 (m, 6H), 1.44 – 1.22 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 173.7, 161.3 
(d, J = 242.7 Hz), 156.5, 138.4, 135.0 (d, J = 2.7 Hz), 133.1, 131.6, 129.3, 129.3 (d, J = 8.1 Hz), 
127.7, 114.9 (d, J = 21.2 Hz), 114.5, 70.4, 70.4, 68.7, 68.6, 68.0, 58.2, 46.8, 46.6, 40.8, 35.5, 33.4, 
31.6, 29.4, 28.2. HRMS (ESI) m/z calcd for C33H38FNO5 [M+H
+
] 548.2812, found 548.2782. 
4.2.5.7. 3-[4-({4-[(4-Methyl-1-oxa-9-azaspiro[5.5]undec-9-
yl)methyl]benzyl}oxy)phenyl]propanoic acid hydrochloride (4h)  
Yield 26 mg (0.06 mmol, 13.6 %). White crystalline solid, m. p. = 183 – 187 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.49 (s, 1H), 7.69 (d, J = 7.8 Hz, 2H), 7.47 (d, J = 7.7 Hz, 2H), 7.12 (d, J = 8.2 
Hz, 2H), 6.92 (d, J = 8.3 Hz, 2H), 5.08 (s, 2H), 4.40 – 4.22 (m, 2H), 3.53 – 3.43 (m, 4H), 3.11 – 
3.01 (m, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.57 (t, J = 7.4 Hz, 2H), 2.46 – 2.37 (m, 1H), 2.13 – 1.88 (m, 
2H), 1.81 – 1.68 (m, 2H), 1.59 – 1.34 (m, 2H), 129 1.11 – 0.81 (m, 5H). 13C NMR (75 MHz, 
DMSO-d6) δ 172.6, 156.6, 138.3, 132.7, 131.5, 129.3, 129.2, 127.7, 114.6, 68.6, 67.8, 60.1, 58.2, 
51.2, 46.8, 43.9, 35.1, 34.0, 29.3, 25.4, 24.4, 22.2. HRMS (ESI) m/z calcd for C27H35NO4 [M+H
+
] 
438.2644, found 438.2598. 
4.2.5.7. 3-(4-{[4-({4-[4-(Trifluoromethyl)benzyl]-1-oxa-9-azaspiro[5.5]undec-9-
yl}methyl)benzyl]oxy}phenyl)propanoic acid hydrochloride (4i)  
Yield 78 mg (0.135 mmol, 30.7 %). White crystalline solid, m. p. = 176 – 185 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.53 (s, 1H), 7.65 (dd, J = 7.96, 18.53 Hz, 4H), 7.45 (d, J = 8.05 Hz, 2H), 7.39 
(d, J = 8.01 Hz, 2H), 7.13 (d, J = 8.51 Hz, 2H), 6.92 (d, J = 8.51 Hz, 2H), 5.08 (s, 2H), 4.38 – 4.22 
(m, 2H), 3.71 – 3.58 (m, 1H), 3.51 – 3.39 (m, 1H), 3.08 – 2.80 (m, 4H), 2.75 (t, J = 7.56 Hz, 2H), 
2.60 – 2.52 (m, 2H), 2.48 (t, J = 7.56 Hz, 2H), 2,44 – 2.39 (m, 1H), 2.10 – 0.99 (m, 8H). 13C NMR 
(75 MHz, DMSO-d6) δ 173.7, 156.5, 144.7 (d, J = 1.0 Hz), 138.4, 133.1, 131.6, 129.8, 129.2, 127.8, 
126.7 (q, J = 31.66 Hz), 125.0 (q, J = 3.63 Hz), 122.7, 114.6, 68.7, 68.0, 60.0, 58.2, 46.8, 46.7, 
42.2, 41.7, 35.6, 35.3, 31.7, 31.3, 29.5, 25.4. HRMS (ESI) m/z calcd for C34H38F3NO4 [M+H
+
] 
582.2831, found 582.2826. 
4.2.5.8. 3-{4-[(4-{[4-(3-Fluorobenzyl)-1-oxa-9-azaspiro[5.5]undec-9-
yl]methyl}benzyl)oxy]phenyl}propanoic acid hydrochloride (4j) 
Yield 29 mg (0.054 mmol, 12.3 %). White crystalline solid, m. p. = 186 – 189 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.55 (s, 1H), 7.69 (d, J = 7.60 Hz, 2H), 7.46 (d, J = 7.68 Hz, 2H), 7.35 – 7.25 
(m, 1H), 7.13 (d, J = 8.19 Hz, 2H), 7.03 – 6.90 (m, 5H), 5.08 (s, 2H), 4.38 – 4.22 (m, 2H), 3.70 – 
3.60 (m, 1H), 3.50 – 3.38 (m, 1H), 3.09 – 2.84 (m, 4H), 2.77 (t, J = 7.55 Hz, 2H), 2.57 (t, J = 7.55 
Hz, 2H), 2.48 – 2.44 (m, 2H), 2,43 – 2.39 (m, 1H), 2.09 – 1.29 (m, 6H), 1.18 – 0.99 (m, 2H). 13C 
NMR (75 MHz, DMSO-d6) δ 172.6, 162.1 (d, J = 243.0 Hz), 156.6, 142.7 (d, J = 7.2 Hz), 138.3, 
132.7, 131.5, 129.9 (d, J = 11.0 Hz), 129.3, 129.2, 127.7, 125.1, 115.7, 115.4, 114.6, 112.8, 112.5, 
68.6, 67.9, 60.1, 59.9, 58.1, 51.2, 46.8, 46.7, 42.1, 41.7, 35.1, 31.8, 31.2, 29.3, 25.4. HRMS (ESI) 
m/z calcd for C33H38FNO4 [M+H
+
] 532.2863, found 532.2858. 
4.2.5.9. 3-{4-[(4-{[4-(4-Fluorobenzyl)-1-oxa-9-azaspiro[5.5]undec-9-
yl]methyl}benzyl)oxy]phenyl}propanoic acid hydrochloride (4k)  
Yield 28 mg (0.052 mmol, 11.8 %). White crystalline solid, m. p. = 200 – 203 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.51 (s, 1H), 7.68 (d, J = 7.73 Hz, 2H), 7.47 (d, J = 7.77 Hz, 2H), 7.29 – 7.04 
(m, 6H), 6.91 (d, J = 8.37 Hz, 2H), 5.08 (s, 2H), 4.38 – 4.21 (m, 2H), 3.72 – 3.57 (m, 1H), 3.52 – 
3.39 (m, 1H), 3.09 – 2.80 (m, 4H), 2.75 (t, J = 7.46 Hz, 2H), 2.49 (t, J = 7.50 Hz, 2H), 2.48 (d, J = 
6.45 Hz, 1H), 2.42 – 2.36 (m, 1H), 2.09 – 1.80 (m, 2H), 1.73 – 1.30 (m, 4H), 1.16 – 0.96 (m, 2H). 
13
C NMR (75 MHz, DMSO-d6) δ 173.6, 160.6 (d, J = 241.1 Hz), 156.5, 138.4, 135.6 (d, J = 3.1 
Hz), 133.1, 131.4, 130.6 (d, J = 7.7 Hz), 129.2, 129.1, 127.6, 114.7 (d, J = 20.9 Hz), 114.5, 68.6, 
67.8, 59.9, 58.3, 46.9, 46.8, 41.6, 35.4, 31.7, 31.4, 29.4, 25.5. HRMS (ESI) m/z calcd for 
C33H38FNO4 [M+H
+
] 532.2863, found 532.2858. 
4.2.5.10. 3-[4-({4-[(4-Benzyl-1-oxa-9-azaspiro[5.5]undec-9-
yl)methyl]benzyl}oxy)phenyl]propanoic acid hydrochloride (4l) 
Yield 68 mg (0.133 mmol, 38 %). White crystalline solid, m. p. = 283 – 188 ºC.  1H NMR (300 
MHz, DMSO-d6) δ 10.97 (s, 1H), 7.64 (d, J = 7.8 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 7.27 (t, J = 7.1 
Hz, 2H), 7.20 – 7.11 (m, 5H), 6.91 (d, J = 8.4 Hz, 2H), 5.08 (s, 2H), 4.39 – 4.22 (m, 2H), 3.62 (dd, 
J = 11.8, 4.8 Hz, 1H), 3.42 (t, J = 11.4 Hz, 1H), 3.13 – 2.80 (m, 4H), 2.74 (t, J = 7.6 Hz, 2H), 2.46 
(t, J = 7.4 Hz, 2H), 2.44 – 2.36 (m, 2H), 2.05 – 1.79 (m, 2H), 1.65 – 1.29 (m, 4H), 1.20 – 0.94 (m, 
2H). 
13
C NMR (75 MHz, DMSO-d6) δ 173.9, 156.6, 139.7, 138.5, 133.1, 131.6, 129.3, 129.3, 
129.0, 128.2, 127.8, 125.9, 114.6, 68.6, 67.9, 60.1, 58.3, 47.0, 46.9, 42.7, 41.8, 35.6, 31.9, 31.5, 
30.7, 29.5, 25.6. HRMS (ESI) m/z calcd for C33H39NO4 [M+H
+
] 514.2957, found 514.2966. 
4.2.5.11. 3-{4-[(4-{[4-(4-Methoxybenzyl)-1-oxa-9-azaspiro[5.5]undec-9-
yl]methyl}benzyl)oxy]phenyl}propanoic acid hydrochloride (4m)  
Yield 98 mg (0.181 mmol, 41 %). White crystalline solid, m. p. = 161 – 165 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.06 (s, 1H), 7.65 (d, J = 7.9 Hz, 2H), 7.48 (d, J = 7.9 Hz, 2H), 7.13 (d, J = 8.4 
Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.4 Hz, 2H), 5.08 (s, 2H), 
4.40 – 4.22 (m, 2H), 3.70 (s, 3H), 3.62 (dd, J = 11.1, 3.5 Hz, 1H), 3.41 (t, J = 11.6 Hz, 1H), 3.13 – 
2.79 (m, 4H), 2.74 (t, J = 7.5 Hz, 2H), 2.48 – 2.29 (m, 5H), 2.03 – 1.75 (m, 2H), 1.62 – 1.28 (m, 
4H), 1.12 – 0.94 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 174.2, 157.9, 157.0, 138.9, 133.5, 
132.0, 131.8, 130.3, 129.79, 129.7, 128.2, 115.0, 114.0, 69.1, 68.3, 60.5, 58.7, 55.3, 47.4, 47.3, 
42.2, 36.0, 35.9, 32.4, 32.1, 29.9, 26.0. HRMS (ESI) m/z calcd for C34H41NO5 [M+H
+
] 544.3063, 
found 544.3057. 
4.2.5.12. 3-{4-[(4-{[4-(4-Methylbenzyl)-1-oxa-9-azaspiro[5.5]undec-9-
yl]methyl}benzyl)oxy]phenyl}propanoic acid hydrochloride (4n) 
Yield 120 mg (0.227 mmol, 51 %). White crystalline solid, m. p. = 148 – 151 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.02 (s, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.13 (d, J = 8.5 
Hz, 1H), 7.04 (dd, J = 14.9, 7.9 Hz, 2H), 6.91 (d, J = 8.5 Hz, 1H), 5.08 (s, 1H), 4.40 – 4.21 (m, 1H), 
3.62 (dd, J = 11.4, 4.0 Hz, 1H), 3.42 (t, J = 11.6 Hz, 1H), 3.11 – 2.79 (m, 2H), 2.74 (t, J = 7.5 Hz, 
1H), 2.49 – 2.36 (m, 3H), 2.25 (s, 2H), 2.02 – 1.78 (m, 1H), 1.63 – 1.27 (m, 2H), 1.17 – 0.96 (m, 
1H). 
13
C NMR (75 MHz, DMSO-d6) δ 173.8, 156.5, 138.5, 136.5, 134.8, 133.1, 131.6, 129.3, 
129.2, 128.9, 128.8, 127.8, 114.6, 68.6, 67.9, 60.1, 58.3, 47.0, 46.9, 42.3, 41.8, 35.5, 32.0, 31.5, 
30.7, 29.5, 25.5, 20.6. HRMS (ESI) m/z calcd for C34H41NO4 [M+H
+
] 528.3114, found 528.3120. 
4.2.5.13. 3-{4-[(4-{[4-(2-Fluorobenzyl)-1-oxa-9-azaspiro[5.5]undec-9-
yl]methyl}benzyl)oxy]phenyl}propanoic acid hydrochloride (4o) 
Yield 16 mg (0.030 mmol, 6.8 %). Hygroscopic solid. 
1
H NMR (300 MHz, DMSO-d6) δ 11.46 (s, 
1H), 7.69 – 7.65 (m, 2H), 7.48 – 7.45 (m, 2H), 7.28 – 7.21 (m, 2H), 7.15 – 7.09 (m, 4H), 6.91 (d, J 
= 8.14 Hz, 2H), 5.07 (s, 2H), 4.38 – 4.22 (m, 2H), 3.72 – 3.58 (m, 1H), 3.50 – 3.37 (m, 1H), 3.07 – 
2.81 (m, 4H), 2.74 (t, J = 7.55 Hz, 2H), 2.56 – 2.51 (m, 2H), 2.48 (t, J = 7.55 Hz, 2H), 2.44 – 2.37 
(m, 1H), 2.04 – 1.84 (m, 2H), 1.69 – 1.29 (m, 4H), 1.20 – 1.02 (m, 2H). 13C NMR (75 MHz, 
DMSO-d6) δ 173.6, 160.5 (d, J = 242.7 Hz), 156.5, 138.3, 133.0, 131.6 (d, J = 4.6 Hz), 131.5, 
129.3, 129.1, 128.1 (d, J = 8.1 Hz), 127.6, 126.2 (d, J = 15.9 Hz), 124.1 (d, J = 3.8 Hz), 115.0 (d, J 
= 21.9 Hz), 114.5, 68.6, 67.8, 59.9, 58.1, 46.8, 46.7, 43.5, 41.6, 35.5, 35.3, 31.8, 29.4, 25.3. HRMS 
(ESI) m/z calcd for C33H38FNO4 [M+H
+
] 532.2863, found 532.2885. 
4.2.5.14. 3-(4-{[4-({4-[(3-Pyridin-3-yl-1,2,4-oxadiazol-5-yl)methyl]-1-oxa-9-azaspiro[5.5]undec-
9-yl}methyl)benzyl]oxy}phenyl)propanoic acid dihydrochloride (4p) 
Yield 61 mg (0.105 mmol, 24 %). White crystalline solid, m. p. = 232 – 235 ºC.  1H NMR (300 
MHz, DMSO-d6) δ 11.50 (s, 1H), 9.26 – 9.19 (m, 1H), 8.90 (d, J = 4.1 Hz, 1H), 8.58 (d, J = 7.0 Hz, 
1H), 7.83 (dd, J = 7.8, 5.2 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.47 (d, J = 7.9 Hz, 2H), 7.13 (d, J = 
8.5 Hz, 2H), 6.91 (d, J = 8.5 Hz, 2H), 5.07 (s, 2H), 4.44 – 4.20 (m, 2H), 3.72 – 3.61 (m, 1H), 3.58 – 
3.45 (m, 1H), 3.12 – 2.81 (m, 6H), 2.73 (t, J = 7.5 Hz, 2H), 2.46 (t, J = 7.4 Hz, 2H), 2.33 – 2.21 (m, 
1H), 2.13 – 1.46 (m, 6H), 1.35 – 1.14 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 179.6, 173.8, 
165.3, 156.6, 149.6, 145.3, 138.4, 137.5, 133.1, 131.6, 129.4, 129.2, 127.7, 125.6, 123.6, 114.6, 
68.7, 68.0, 59.8, 58.3, 46.8, 41.2, 35.6, 35.3, 32.5, 31.4, 30.7, 29.5, 28.6. HRMS (ESI) m/z calcd for 
C34H38N4O5 [M+H
+
] 583.2920, found 583.2924. 
4.2.5.15. 3-(4-{[4-({4-[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-1-oxa-9-
azaspiro[5.5]undec-9-yl}methyl)benzyl]oxy}phenyl)propanoic acid hydrochloride (4q) 
Yield 67 mg (0.123 mmol, 28 %). White crystalline solid, m. p. = 179 – 184 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.45 (s, 1H), 7.68 (d, J = 6.40 Hz, 2H), 7.47 (d, J = 6.08 Hz, 2H), 7.12 (d, J = 
7.41 Hz, 2H), 6.91 (d, J = 7.51 Hz, 2H), 5.07 (s, 2H), 4.39 – 4.24 (m, 2H), 3.68 – 3.59 (m, 1H), 3.52 
– 3.39 (m, 1H), 3.11 – 2.99 (m, 3H), 2.87 – 2.70 (m, 5H), 2.48 – 2.39 (m, 3H), 2,18– 2,01 (m, 3H), 
1.79 – 1.38 (m, 4H), 1.23 – 0.99 (m, 4H), 0,88 – 0.82 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 
177.8, 173.6, 171.5, 156.5, 138.3, 133.0, 131.5, 129.3, 129.1, 127.6, 114.5, 68.6, 67.8, 59.7, 58.1, 
46.7, 35.5, 32.3, 31.3, 29.4, 28.3, 25.3, 7.3, 6.2. HRMS (ESI) m/z calcd for C32H39N3O5 [M+H
+
] 
546.2968, found 546.2962. 
4.2.5.16. 3-[4-({4-[(4-{[3-(2-Methoxyethyl)-1,2,4-oxadiazol-5-yl]methyl}-1-oxa-9-
azaspiro[5.5]undec-9-yl)methyl]benzyl}oxy)phenyl]propanoic acid hydrochloride (4r)  
Yield 98 mg (0.174 mmol, 40 %). White crystalline solid, m. p. = 166 – 176 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 10.87 (s,1H), 7.56 (ABq, J = 8.10, 45.05 Hz, 4H), 7.03 (ABq, J = 8.60, 57.86 
Hz, 4H), 5.08 (s, 2H), 4.38 – 4.24 (m, 2H), 3.68 – 3.62 (m, 3H), 3.54– 3.45 (m, 1H), 3.21 (s, 3H), 
3.09 – 3.03 (m, 3H), 2.92 - 2.81 (m, 5H), 2.74 (t, J = 7.64 Hz, 2H), 2.49 – 2.44 (m, 3H), 2.25 – 2.10 
(m, 1H), 2.07 – 1.85 (m, 1H), 1.68 – 1.42 (m, 4H), 1.24 – 1.05 (m, 2H). 13C NMR (75 MHz, 
DMSO-d6) δ 177.9, 173.6, 168.0, 156.5, 138.5, 133.1, 131.4, 129.2, 129.1, 127.1, 114.5, 68.6, 68.3, 
67.8, 59.7, 58.3, 57.8, 46.8, 41.1, 35.4, 35.3, 32.3, 31.3, 29.4, 28.3, 25.9, 25.4. HRMS (ESI) m/z 
calcd for C32H41N3O6 [M+H
+
] 564.3074, found 564.3083. 
4.2.5.17. 3-(4-{[4-(1-Oxa-9-azaspiro[5.5]undec-9-ylmethyl)benzyl]oxy}phenyl)propanoic acid 
hydrochloride (4s) 
Yield 12 mg (0.029 mmol, 6.6 %). White crystalline solid, m. p. = 194 – 199 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 11.38 (s, 1H), 7.68 (d, J = 7.5 Hz, 2H), 7.48 (d, J = 7.6 Hz, 2H), 7.13 (d, J = 8.1 
Hz, 2H), 6.91 (d, J = 8.2 Hz, 2H), 5.08 (s, 2H), 4.39 – 4.22 (m, 2H), 3.53 (br s, 2H), 3.1-2.87 (m, 
4H), 2.74 (t, J = 7.3 Hz, 2H), 2.48 (t, J = 7.8 Hz, 2H), 2.03 (d, J = 14.2 Hz, 2H), 1.84 (t, J = 12.7 
Hz, 2H), 1.6-1.3 (m, 6H). 
13
C NMR (75 MHz, DMSO-d6) δ 173.7, 156.5, 138.3, 133.0, 131.5, 
129.4, 129.2, 127.7, 114.55, 68.6, 67.3, 60.1, 58.2, 46.7, 35.5, 35.1, 30.7, 30.1, 29.4, 25.3, 18.1. 
HRMS (ESI) m/z calcd for C26H33NO4 [M+H
+
] 424.2488, found 424.2502. 
4.3 Molecular modeling 
4.3.1. Protein structure source and preparation for docking 
The 3D coordinates for FFA1 co-crystalized with TAK-875 were obtained from the Protein Data 
Bank (PDB ID: 4PHU) and used for subsequent docking procedures.
23
 Protein preparation, 
refinement and docking was performed within Schrödinger’s Maestro, version 2016-1.24  To 
prepare FFA1 for docking, hydrogens and missing atoms were added, alternate residue positions 
were defined and the hydrogen bonding network was further optimized by re-orientating hydroxyls, 
amides and imidazole rings (of histidine residues) using Protein Preparation Wizard.
25
   
4.3.2. Docking protocol. 
In the crystallized FFA1, four point mutations (Leu42-Ala, Phe88-Ala, Gly103-Ala, Tyr202-Phe) 
were made to increase expression of the protein and to improve thermal stability. The mutant 
Ala88, positioned between TM3 and TM4 can be considered an important residue in stabilizing the 
binding conformations.
26
 Therefore, this residue was mutated in silico back to Phe with extensive 
conformational sampling using the MacroModel Conformational Search.
27
 To alleviate any strain 
occurring from this point mutation, a stringent two-step minimization protocol was employed, i.e. 
hydrogen-only minimization followed by a constrained minimization based on the X-Ray derived 
B-Factors, implemented with MacroModel.
27
 In determining the final position of the benzyl side-
chain in 4l and for selecting an appropriate docking protocol, TAK-875 was re-docked onto FFA1 
and compared to the crystal structure orientation, RMSD < 2.5 Å.  Furthermore, in determining a 
correct docking pose an appreciation of the membrane positioning was made using the Orientation 
of proteins in membrane (OPM) database and PPM webserver to align and perdict the position of 
the GPR40 receptor in a membrane.
28
 Ligands were created manually in the Schrödinger Maestro 
2D sketcher and prepared using LigPrep
29
 to produce a low energy conformation. Receptor grid 
generation and docking was performed using GLIDE
30
 with the extra precision (XP) algorithm 
while enhancing the planarity of conjugated pi groups. The centroid of the grid was defined by the 
center of mass of TAK-875 as positioned in the crystal structure. In all calculations the OPLS3, all 
atom force-field was utilized. To allow the comparison of residue positions within the GPCR 
family, the labels in figure 1 and figure 2 shown the Ballesteros Weinstein indexing system in 
subscript.
21
 Images were rendered using two separate programs: maestro to represent the specific 
protein-ligand interactions and VMD v1.9.2
31
 to visualize the membrane position and surface 
representations.  
4.4 Biological and ADME assays 
4.4.1. Determination of agonistic activity of compounds against FFA1 (GPR40), FFA3 
(GPR41), FFA2 (GPR43) and FFA4 (GPR120) receptors 
CHO cells stably expressing human GPR40 (stable CHO-GPR40 line created at Enamine Ltd.) were 
seeded (12500 cells/well) into 384-well black-wall, clear-bottom microtiter plates 24 h prior to 
assay. Cells were loaded for 1 h with fluorescent calcium dye (Fluo-8 Calcium Assay kit, Abcam, 
ab112129) and tested using fluorometric imaging plate reader (FLIPR Tetra
®
 High Throughput 
Cellular Screening System, Molecular Devices Corp.). Maximum change in fluorescence over base 
line was used to determine agonist response. A potent and selective agonist for FFA1 (GPR40) 
GW9508 (Selleckchem, S8014) was tested with the test compounds as a positive control. 
Concentration response curve data were fitted using Molecular Devices ScreenWorks® System 
Control Software (Molecular Devices). For specificity screening for possible GPR41, GPR43 and 
GPR120agonism, CHO cell lines stably expressing the respective receptors (purchased from The 
European Collection of Cell Cultures, ECACC) were used. 
4.4.2. Determination of aqueous solubility (PBS, pH 7.4) 
The test compounds (4k-n) and the reference compound (Ondansetron hydrochloride, Sigma-
Aldrich, O3639), were assessed for kinetic solubility in phosphate-buffered saline: 138 mM NaCl, 
2.7 mM KCl, 10 mM K-phosphate, pH 7.4 with 2% final DMSO. Solubility measurements were 
done using filter microplate technique with UV-quantification for all compounds. Using a 40 mM 
stock solution of each compound in 100% DMSO, dilutions were prepared to a theoretical 
concentration of 800 μM in duplicates in phosphate-buffered saline pH 7.4 with 2% final dimethyl 
sulfoxide (DMSO) and then transferred to a 96-well, deep well polypropylene collection plate. In 
parallel, compound dilutions in 50% methanol/PBS mixes were prepared at concentrations of 0 μM 
(blank), 200 μM and 400 μM in duplicates to generate calibration curves. The experimental 
compound dilutions in PBS were further allowed to equilibrate at 25°C on a thermostatic orbital 
shaker for two hours and then filtered through HTS solubility filter plates (EMD Millipore, 
MSSLBPC)  using a vacuum manifold. The filtrates adjusted for the calibration sample non-
aqueous solvent content by 2-fold dilution with methanol, and the calibrating solutions were 
analyzed using SpectraMax UV-Vis microplate reader (200-550 nm absorbance scan, 5 nm step 
increment). The concentrations of compounds in PBS filtrate were determined using a dedicated 
Microsoft Excel calculation script. Proper absorbance wavelengths for calculations were selected 
for each compound manually based on absorbance maxima (absolute absorbance unit values for the 
minimum and maximum concentration points within 0 - 3 OD range). Each of the final datasets was 
additionally visually evaluated by the operator and goodness of fit (R2) was calculated for each 
calibration curve. The reference compound was included in every separate solubility experiment to 
control proper assay performance.  
4.4.3. Assessment of metabolic stability in mouse liver microsomes 
The metabolic stability of compounds 4k-n as well as the reference compounds (Imipramine, 
Propranolol) was determined in liver microsomes at five time points over 40 minutes using HPLC-
MS.  
Mouse hepatic microsomes were isolated from pooled (50), perfused livers of BALB/c male mice 
according to the standard protocol.
32
 The batch of microsomes was tested for quality control using a 
commercial comparator preparation (Sigma-Aldrich M9441) and verapamil and propranolol as 
reference compounds. Microsomal incubations were carried out in 96-well plates in 5 aliquots of 40 
μL each (one for each time point). Liver microsomal incubation medium contained potassium 
phosphate buffer (100 mM, pH 7.4), MgCl2 (3.3 mM), NADPН (3 mM), glucose-6-phosphate (5.3 
mM), glucose-6-phosphate dehydrogenase (0.67 units/ml) with 0.42 mg of liver microsomal protein 
per ml. In addition, control incubations were performed replacing the NADPH-regenerating system 
with 100 mM phosphate buffer pH 7.4. Test compounds (2 μM, final solvent concentration 1.6 %) 
were incubated at 37°C under vortexing at 100 rpm. Five time points over 40 minutes had been 
analyzed. The reactions were stopped by adding 12 volumes of 90% acetonitrile-water to 40 μL 
incubation aliquots, followed by plasma protein precipitation by centrifuging at 5500 rpm for 3 
minutes. Incubations were performed in duplicates. Supernatants were analyzed using the HPLC 
system coupled with tandem mass spectrometer. The elimination constant (kel), half-life (T1/2) and 
intrinsic clearance (Clint) were determined in plot of ln(AUC) versus time, using linear regression 
analysis: 
kel = - slope 
T1/2 = 0.693/kel 
CLint = (0.693/ T1/2) x (l incubation/mg microsomes) 
4.4.4. Analysis of plasma protein binding 
The binding of compounds 4k-n as well as the reference compound (Verapamil) to human plasma 
proteins was evaluated using HPLC-MS/MS. The task was performed by spiking test compounds at 
concentration of 1 μM into mice plasma (Lampire Biological Labs, US, catalog number 7304309) 
and dialyzing against buffer until equilibrium is achieved. Concentrations of the compounds in both 
plasma and buffer were determined to calculate the percentage of plasma protein bound compounds. 
The assay was performed in the 96-well equilibrium dialysis apparatus (HTDialysis, LLC). Each 
individual well unit consisted of 2 chambers separated by a vertically aligned dialysis membrane of 
predetermined pore size (MWCO 12-14 kDa). 120 μl of plasma spiked with the compound (1 μM, 
final solvent concentration 1%) was added to one chamber and the same aliquot of PBS buffer, pH 
7.4 was added to the other chamber. After that, HTD96b dialyzer was covered with adhesive sealing 
film and incubated at 37°C on an orbital shaker at 100 rpm for 5 hours. An aliquot of the content of 
each chamber was taken and mixed with the same volume aliquot of the blank opposite matrix. In 
order to define non-specific loss of the compound during this assay, standard solution was created 
by mixing an aliquot of spiked plasma, which was incubated at 37°C without dialysis, with blank 
buffer. Sample of 1 μM series was diluted with 100% acetonitrile 10-fold with subsequent plasma 
proteins precipitation by centrifuging at 6000 rpm for 5 minutes. Incubations were performed in 
quadriplicates. Supernatants were analyzed using HPLC system coupled with tandem mass 
spectrometer. The unbound compound fraction was calculated as the peak ratio of the analyte in the 
buffer compartment divided by the same parameter in the corresponding plasma compartment. The 
following equation was used to determine the extent of plasma protein binding: 
 
 
4.4.5. Caco-2 permeability determination 
In each experiment, reference compounds Atenolol (Sigma-Aldrich, A7655), Propranolol (Sigma-
Aldrich, P0884), Testosterone (Sigma-Aldrich, T1500) were tested along with the test compounds 
in order to assess the assay suitability. The integrity of the cell monolayer was verified by 
measuring the transepithelial electrical resistance (TEER) for every well using the Millicell-ERS 
system Ohm meter. 
The concentrations of compound 4k-n in the A-B permeability assay were determined using HPLC-
MS method. The LC system comprised a Shimadzu liquid chromatograph equipped with isocratic 
pumps (Shimadzu LC-10ADvp), an autosampler (Shimadzu SIL-HTc), a switching valve (FCV-
14AH) and a degasser (Shimadzu DGU-14A). Mass spectrometric analysis was performed using an 
API 3000 (triple-quadrupole) instrument from AB Sciex (USA) with an electro-spray (ESI) 
interface. The data acquisition and system control was performed using Analyst 1.5.2 software from 
AB Sciex. 
The formula for calculating Papp was as follows: 
Papp=(VA/((Area)x(Time))x([drug]acc/[drug]initial,d) 
Where VA – volume of transport buffer in acceptor well, 
Area – surface area of the insert (equals to effective growth area of the insert - 0.31 sq.cm), 
Time – time of the assay, 
[drug]acc – concentration of test compound in acceptor well, 
[drug]initial,d – initial concentration of test compound in a donor well. 
Papp is expressed in 10
-6
cm/sec. 
 
Data obtained for the reference compounds: 
Compound Test concentration (μM) 
Permeability (10
-6
 cm/s) 
1
st
 2
nd
 Mean SD 
Atenolol 10 2.59 3.15 2.87 0.40 
Propranolol 10 25.83 30.12 27.97 3.04 
Testosterone 10 15.86 11.36 13.61 3.19 
 
4.4.6 Mouse pharmacokinetic study 
Animals. Male JAXC57BL/6J mice, supplied by the Laboratory Animal Centre (University of 
Eastern Finland, Kuopio, Finland), were housed in stainless steel cages and kept on a 12-h light/12-
h dark cycle (lights on at 7:00 AM) at an ambient temperature of 22 ± 2 °C and humidity 55 ± 15 
%. Pelleted food (Teklad 2016S, Envigo, the Netherlands) and fresh tap water were available ad 
libitum. Animals were 8-10 weeks old and weighed 20 to 27 g (n = 50). All experiments were 
performed in accordance with European Union guidelines (Directive 2010/63/EU and guidelines 
2007/526/EC) and approved by the National Animal Experiment Board of Finland (project licence 
number ESAVI-2015-002090). 
Drug administration and sampling. For intravenous and oral administration, 4k was dissolved in 10 
% β-cyclodextrin. Mice were placed into a restraining device and a bolus injection of 4k (10 mg/kg) 
was given via a tail vein. Oral single dose of 4k (10 mg/kg) was given by a plastic gavage. A dosing 
volume of 5 ml/kg was used. Mice were anesthetized by pentobarbital (0.1 ml/10 g, i.p.; Mebunat 
60 mg/ml, Orion Pharma Finland) and decapitated 10, 30, 60, 120, 240 min after intravenous 
administration or 30, 60, 120, 240 and 360 min after oral administration (n=5 in each time point). 
Blood samples were taken by a cardiac puncture using heparinized syringe and plasma was 
separated by centrifugation for 10 min at 2 000 g at +4°C. The plasma samples were transferred into 
plastic tubes and stored at −70°C until analyzed. 
Drug analysis.  The concentrations of compound 4k in the pharmacokinetic study were determined 
using quantitative HPLC-MS method. The LC system comprised an Agilent liquid chromatograph 
system (Agilent 1200 series rapid resolution LC system, Agilent Technologies, Waldbronn, 
Germany). Mass spectrometric analysis was performed using an Agilent 6410 Triple Quadrupole 
MS equipped with an electrospray ionization source (Agilent Technologies, Palo Alto, CA, USA). 
Data were acquired by Agilent MassHunter Workstation Acquisition software (version B.01.03). 
Pharmacokinetic calculations. The apparent pharmacokinetic parameters, maximum plasma 
concentration (Cmax), time to reach Cmax (Tmax), area under curve (AUC), and clearance (Cl) were 
calculated from group data by using a linear trapezoidal rule with linear interpolation and Phoenix 
WinNonlin 6.3 software (Pharsight/Cetara, Princeton, NJ, USA). No compound 4k was detected in 
plasma at 360 min after oral administration and thus, 360 min time point was excluded from 
pharmacokinetic calculations. Oral bioavailability (F) was calculated using the following equation: 
F = AUC0-∞ oral/AUC0-∞ i.v. × 100 %. 
Acknowledgements 
This research was supported by the Russian Scientific Fund (project grant 14-50-00069). We are 
grateful to the Center for Chemical Analysis and Materials Research of Saint-Petersburg State 
University for providing high-resolution mass-spectrometry data. 
Supplementary data 
Supplementary data associated with this article can be found, in the online version, at 
http://dx.doi.org/xxx. 
 
 
References and notes 
1. Briscoe, C. P.; Tadayyon, M.; Andrews, J. L.; Benson, W. G.; Chambers, J. K.; Eilert, M. M.; 
Ellis, C.; Elshourbagy, N. A.; Goetz, A. S.; Minnick, D. T.; Murdock, P. R.; Sauls, H. R.; Shabon, 
U.; Spinage, L. D.; Strum, J. C.; Szekeres, P. G.; Tan, K. B.; Way, J. M.; Ignar, D. M.; Wilson, S.; 
Muir, A. I. J. Biol. Chem. 2003, 278, 11303−11311.  
2. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, 
M.; Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; 
Komatsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. 
Nature 2003, 422, 173-176.  
3. Watterson, K. R.; Hudson, B. D.; Ulven, T.; Milligan, G. Front. Endocrinol. 2014, 5, 137. 
4. Defossa, E.; Wagner, M. Bioorg. Med. Chem. Lett. 2014, 24, 2991-3000. 
5. https://clinicaltrials.gov, last accessed on July 21, 2016. 
6. Kaku, K.; Enya, K.; Nakaya, R.; Ohira, T.; Matsuno, R. Diabetes Obes. Metab. 2015, 17, 675-
681. 
7. Mancini, A. D.; Poitout, V. Diabetes Obes. Metab. 2015, 17, 622-629. 
8. Zahanich, I.; Kondratov, I.; Naumchyk, V.; Kheylik, Y.; Platonov, M.; Zozulya, S.; Krasavin, 
M. Bioorg. Med. Chem. Lett. 2015, 25, 3105-3111. 
9. Krasavin, M.; Lukin, A.; Zhurilo, N.; Kovalenko, A.; Zahanich, I.; Zozulya, S. J. Enzyme Inhib. 
Med. Chem. 2016, DOI: 10.3109/14756366.2016.1142984. 
10. Krasavin, M.; Lukin, A.; Zhurilo, N.; Kovalenko, A.; Zahanich, I.; Zozulya, S.; Moore, D.; 
Tikhonova, I. G. Bioorg. Med. Chem. 2016, 24, 2954-2963. 
11. Zheng, Y.; Tice, C. M.; Singh, S. B. Bioorg. Med. Chem. Lett. 2014, 24, 3673-3682.  
12. Pastor, I. M.; Yus, M. Curr. Org. Chem. 2007, 11, 925-957. 
13. Ghosh, A. K.; Shin, D.; Schiltz, G. Heterocycles 2002, 58, 659-666. 
14. Lukin, A.; Bagnyukova, D.; Kalichenkova, N.; Zhurilo, N.; Krasavin, M. Tetrahedron Lett. 
2016, 57, 3311-3314. 
15. (a) Borzilleri, R. M.; Perez, H. L.; Wei, D. D.; Kim, K. S.  PCT Int. Appl. WO 2014025759A1; 
Chem. Abstr. 2014, 160, 341383; (b) Amombo, G. M.; Kramer, T.; Lo Monte, Fabio; Goering, S.; 
Fach, M.; Smith, S.; Kolb, S.; Schubenel, R.; Baumann, K.; Schmidt, B. Bioorg. Med. Chem. Lett. 
2012, 22, 7634-7640. 
16. Briscoe, C. P.; Peat, A. J.; McKeown, S. C.; Corbett, D. F.; Goetz, A. S.; Littleton, T. R.; 
McCoy, D. C.; Kenakin, T. P.; Andrews, J. L.; Ammala, C.; Fornwald, J. A.; Ignar, D. M.; 
Jenkinson, S. Br. J. Pharmacol. 2006, 148, 619-628. 
17. Ichimura, A.; Hirasawa, A.; Hara, T.; Tsujimoto, G. Prostaglandins Other Lipid Mediat. 2009, 
89, 82-88. 
18. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; 
Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; 
Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. ACS Med. Chem. Lett. 2010, 1, 290-294. 
19. Brown, J. A.; Goldsworthy, S. M.; Barnes, A. A.; Ellert, M. M.; Tcheang, L.; Daniels, D.; 
Muir, A. I.; Wogglesworth, M. J.; Kinghorn, I.; Fraser, N. J.; Pike, N. B.; Sturn, J. C.; Steplewski, 
K. M; Murdoch, P. R.; Holder, J. C.; Marshall, F. H.; Szekeres, P. G.; Wilson, S.; Ignar, D. M.; 
Foord, M. S.; Wise, A.; Dowell, S. J. J. Biol. Chem. 2003, 278, 11312-11319. 
20. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; 
Miyazaki, S.; Tsujimoto, G. Nat. Med. 2005, 11, 90-94. 
21. Ballesteros, J.; Weinstein, H. Biophys. J. 1995, 68, A446. 
22. Smith, D. A.; Di, L.; Kerns, E. H. Nat. Rev. Drug Discov. 2010, 9, 929-939. 
23. Srivastava, A.; Yano, J.; Hirozane, Y.; Kefala, G.; Gruswitz, F.; Snell, G.; Lane, W.; Ivetac, A.; 
Aertgeerts, K.; Nguyen, J.; Jennings, A.; Okada, K. Nature 2014, 513, 124-129. 
24. Schrödinger, Maestro version 10.5, LLC, New York, NY, 2016. 
25. Sastry, G. M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W.  J. Comput. Aid. Mol. 
Des. 2013, 27, 221–234. 
26. Tikhonova, I. G.; Poerio, E. BMC Structural Biology 2015, 15, 16. 
27. Schrödinger, Macromodel version 11.1, LLC, New York, NY, 2016. 
28. Lomize, M. A.; Pogozheva, I. D.; Joo, H.; Mosberg, H. I.; Lomize, A. L. OPM database and 
PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 2012, 40, 
D370-376. 
29. Schrödinger, Ligprep version 3.7, LLC, New York, NY, 2016. 
30. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; 
Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. J. 
Med. Chem. 2004, 47, 1739-1749. 
31. Humphrey, W.; Dalke, A.; Schulten, K. J. Mol. Graph. 1996, 14, 33-38. 
32. Hill, J. R. In Current Protocols in Pharmacology 7.8.1-7.8.11, Wiley Interscience, 2003. 
Page 1
Bioorganic and Medicinal Chemistry
jo-
as
COMPUTATIONAL DATA in 
Supplementary Information
PURITY
CHECKLIST FOR COMPOUND CHARACTERIZATION
only for new/unknown compounds
TO DISPLAY INSTRUCTIONS:  Double-click HERE   (Formula Bar must be visible: Select  View>Formula Bar)  TO CLOSE: Enter/Return
IDENTITYCOMPOUND
Novel free fatty acid receptor 1 (GPR40) agonists based on 
1,3,4-thiadiazole-2-carboxamide scaffold
Corresponding Author Mikhail Krasavin
 T
it
le
BMC
Compound No. ne
w
kn
ow
n
M
el
tin
g 
po
in
t
IR U
V
-V
is
1H
 N
M
R
13
C
 N
M
R
__
_ 
N
M
R
M
S
H
R
M
S
Sp
ec
ifi
c 
ro
ta
tio
n
1H
/1
3C
 N
M
R
 s
pe
ct
ru
m
 in
 S
up
pl
em
en
ta
ry
 In
fo
rm
at
io
n
C
hr
om
at
og
ra
m
 in
 S
up
pl
em
en
ta
ry
 In
fo
rm
at
io
n
El
em
en
ta
l a
na
ly
si
s
<> C
ar
te
si
an
 c
oo
rd
in
at
es
 o
r 
Z-
m
at
ri
x
# 
of
 im
ag
in
ar
y 
fr
eq
ue
nc
ie
s
To
ta
l e
ne
rg
y
x x
7 x x x x x x
8 x x x x x x
1 x x x x x x
10 x x x x x x
11 x x x x x x
3a x x x x x x
3b x x x x x x
3c x x x x x x
3d x x x x x x
3e x x x x x x
3f x x x x x x
3g x x x x x x
3h x x x x x x
*Compound Characterization Checklist
Supplementary Material
Click here to download Supplementary Material: Krasavin_Supplementary data.pdf
